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Abstract 
  
Human proteins carry out much of their functions in cells by forming specific 
complexes with other proteins. Understanding the molecular mechanism of cellular 
processes requires insights into structural properties of protein-protein interactions at 
an atomic scale. This information is crucial also for progress in pharmacological 
research. Unfortunately, determining high-resolution structures of proteins by 
experimental methods is not trivial. Indeed, up to now, only little information about 
the structures of human protein-protein complexes is available. 
 
Computational approaches, such as structural bioinformatics and molecular 
simulation, have greatly contributed to the understanding of how proteins and their 
complexes are structured and organized in space and time. This can be achieved for 
either native or non-native conditions that are difficult to obtain experimentally. Here 
I have applied computational methods to unravel key structural aspects of 
pharmacologically relevant protein complexes in vitro (i) as well as to elucidate 
electrospray ionization (ESI) mass spectrometry (MS) experiments of protein 
complexes (ii). 
 
(i) Specifically, I have focused on cyclin-dependent kinase 2 (CDK2), one of the 
central regulators of cell growth and division, the dysregulation of which plays a role 
in various diseases. However, structural information of CDK2 in complex with some 
of its in vivo substrate is still missing. By using molecular docking, I modeled CDK2 
complexes with two of its in vivo cellular partners, the full-length sirtuin 2 (SIRT2) 
and a p27KIP1 C-terminal peptide. The two proteins turn out to bind to CDK2 
comparably to a short model peptide (Brown N.R., et al. Nature Cell Biol. 1999, 1, 
438). Of note, my work identified additional relevant interactions not predicted by the 
published work that might be important to design inhibitors. This investigation 
required to predict the full-length structure of SIRT2. This protein itself is a potential 
pharmacological target for both neurodegenerative diseases and cancer. By using 
bioinformatics tools and molecular dynamics (MD) simulations, I provide the first 
full-length models of SIRT2, as well as insights into the auto-regulatory mechanism 
of its catalytic activity. My in silico models, complemented by in vitro deacetylation 
assays from Prof. Lüscher’s lab, provide a consistent picture based on which the C-
terminal region of SIRT2 is suggested to function as an auto-inhibitory region. 
Furthermore, my simulations suggest that the phosphorylation at S331 causes large 
conformational changes in the C-terminal region that enhance the auto-inhibitory 
activity.  
 
(ii) Next, I have investigated the applicability of ESI-MS-based techniques, widely 
used in proteomics, for structural predictions of protein-protein complexes. These 
techniques rely on the assumption that non-covalent protein complexes being 
transferred into the gas phase preserve basically the same intermolecular interactions 
as in solution. Therefore I have extended an in-house protocol for structural prediction 
of single proteins in ESI-MS to the human insulin dimer (hIns2). This protein complex 
is of pharmacological relevance, as insulin resistance or deficiency is associated with 
diabetes and age-related neurodegenerative diseases. My calculations not only 
correctly reproduced the experimental observables, but they also showed that the 
overall gas-phase structure of hIns2 does exhibit differences with the one in aqueous 
solution, not inferable from experimental observables.  
 
In summary, my work has demonstrated two applications of advanced computational 
methods to the investigations of pharmacological relevant complexes. On one hand, 
by facing the challenge of predicting the conformational ensemble of intrinsically 
disordered proteins, I was able to show that SIRT2 and p27KIP1 may share a similar 
mode of binding to CDK2 as reported for a small model peptide with CDK2. On the 
other hand, by performing a combination of quantum chemical, Monte Carlo and 
advanced MD simulations, I have shown that care should be exerted when 
interpreting ESI-MS proteomics data for structural predictions. 
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Chapter 1 Introduction 
Human proteins carry out much of their functions in cells by interacting with other 
proteins [1-5]. These interactions are used to maintain complex regulatory and 
metabolic networks [1-10]. Construction of a proteome-wide description of these 
interactions, the so-called interactome, is key to understand the functional and 
regulatory pathways of proteins 1  [18]. In this context, the major challenge of 
uncovering structural properties of the interactome - likely to include as many as 
~650,000 distinct pairwise interactions [19] - may greatly impact on medicine and on 
drug discovery [20-24]. Unfortunately, experimental high-resolution structural 
information is available only for roughly 6% of the interactome at present [25]. The 
information is complemented by low-to-intermediate resolution techniques, such as 
electrospray/ion mobility (ESI/IM) mass spectrometry (MS) [26], cryo-electron 
microscopy [27] and small-angle X-ray scattering [28]. In spite of these advances, 
structural information on most of the interactome is lacking. Structural predictions of 
protein-protein complexes are then often the method of choice to get insight on 
protein-protein interactions [29,30]. This thesis offers two examples of 
pharmaceutically relevant proteins for which I performed structural predictions, i.e. 
the human cyclin-dependent kinase 2 (CDK2) in complex the CDK inhibitor p27KIP1 
and the nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase sirtuin 2 
(SIRT2) and the analysis of human insulin dimer (hIns2). 
 
The first part of my thesis focuses on the human CDK2 that regulates cell 
proliferation by controlling cell cycle progression [31,32]. The deregulation of CDK2 
and thus altered substrate phosphorylation is associated with a number of different 
diseases, including cancer and neurodegeneration [33-44]. Here, we have predicted 
the binding of CDK2 with two in vivo cellular substrates, p27KIP1 and the SIRT2. The 
investigation of the latter required substantial initial work on the structural prediction 
of SIRT2. SIRT2 regulates cellular metabolism [45] and has been associated with 
aging process and cancer [46-51]. The structure of the catalytic domain of SIRT2 has 
                                                
1Classification methods, such as the yeast two-hybrid system [11], mass spectrometry [12], 
tandem affinity purification [13], immunoprecipitation [14], pulldown arrays [15], protein 
chips [16] and phage display [17], determine protein-protein interactions. 
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been solved [52]. However, structural information of the C-terminal and N-terminal 
regions that are potentially important to control its catalytic activity and thus its 
function is missing. This information might contribute to design specific inhibitors to 
control SIRT2 deacetylation activity for therapeutic applications. Hence, I have 
initially predicted the first full-length molecular models of apo-SIRT2, SIRT2 in 
complex with NAD+ (SIRT2/NAD+), and S331 phosphorylated SIRT2 (SIRT2-
pS331) using bioinformatics tools and molecular dynamics (MD) simulations. My in 
silico models, combined with in vitro approaches, provides a consistent picture based 
on which the C-terminal region may function as an autoinhibitory region by partially 
occluding the NAD+ binding site in SIRT2 or stabilizing the NAD+ in a non-
productive state in SIRT2/NAD+. This occlusion is increased by phosphorylation at 
S331.  
 
For p27KIP1, which has been suggested to function as tumor suppressor [53] but more 
recently has also been attributed oncogenic functions [54], I modeled the C-terminal 
region where the CDK2-dependent phosphorylation site [53], T187, is located. This 
structural prediction was used for my further studies. 
 
Next, I have performed docking calculations of SIRT2 or p27KIP1 with their target 
protein CDK2. The calculations suggest that these substrates display a similar mode 
of binding to CDK2 as predicted from a crystal structure of a model peptide in 
complex with CDK2 [55]. The identified structural determinants of such interactions 
can be fruitfully used as templates for drug-design approaches.  
 
The second study concerns a structural prediction of protein complexes in near ESI-
MS conditions. ESI-MS is used to provide insight into structural proteomics [9,23,56-
62] under the assumption that non-covalent protein complexes that are being 
transferred into the gas phase preserve basically the same intermolecular interactions 
as in solution [63-67]. Here I have investigated the applicability of this assumption by 
extending a structural prediction protocol for single proteins in ESI-MS from our 
group [68] to protein complexes. I have applied the protocol to the hIns2 as a test case. 
The predictions reproduce the experimental main charge state and collision cross 
section (CCS). They further show that, in the sub-ms time scale the overall gas-phase 
structure of the complex rearranges already significantly. The final gas-phase 
 8 
structure differs distinctively from the solution structure as large amplitude 
reorganizations take place in order to maximize intra- and intermolecular hydrogen 
bond interactions. Hence, this work provides evidence against the assumption that 
non-covalent complexes being transferred into the gas phase generally preserve their 
structural determinants in solution. The established protocol may be of help for the 
development of efficient strategies to optimize experimental factors to control the 
gaseous protein ion structure in ESI-MS experiments. 
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Chapter 2 Biological background 
In this chapter, basic background (e.g. structure and cellular functions) of the 
biomolecules investigated in this thesis is provided. 
2.1 Biomolecules investigated in this thesis  
2.1.1 CDK2 
Cyclin-dependent kinases (CDK) phosphorylate key substrates involved in cell cycle 
progression [69,70], strictly regulating the proceeding of the four phases: S 
(synthesis), M (mitosis) and two gap phases (G1 and G2) that separate the M and S 
phases (see Appendix A1). Human CDK2 is the key agent in controlling passage 
through G1 into S phase [71]. Therefore, inhibition of CDK2 activity is considered a 
potential target for diseases affecting proliferation, such as cancer [72,73]. 
 
CDKs are “cyclin” dependent since they are transiently activated by cyclins, i.e. they 
are active only when binding with cyclins [74], and next deactivated by CDK 
inhibitors (CKI) [75,76].  
 
Kinase activity of CDK2 is specifically positively regulated by the binding of cyclins 
(A or E, cyclin A/CDK2 or cyclin E/CDK2) and phosphorylation at T160 (pT160) on 
its activation loop by CDK-activating kinase (CAK) [77-79]. While its catalytic 
activity is inhibited by endogenous CKIs (p21CIP1 and p27KIP1) and by the 
phosphorylation at T14 and Y15 [55]. Crystallographic studies on CDK2 have 
provided a detailed understanding of the structural basis of the regulation of CDK2 
activity by cyclin A and p27KIP1 binding and phosphorylation [55,77,78,80].  
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Figure 2.1: Crystal structure of cyclin A/CDK2 bound to p27KIP1 (PDB ID: 1JSU 
[80]). The cartoon representations of N-terminal and C-terminal lobes of CDK2, 
cyclin A, and p27KIP1 are colored in blue, red, orange, and green, respectively. The 
activating phosphorylation of CDK2 at T160 (pT160) and RXL motif at p27KIP1 (R30, 
N31 and L32) recognized by cyclin are represented by sticks and spheres, 
respectively. 
 
The structure of CDK2 consists of two lobes: an N-terminal lobe (residues 1-85) rich 
in β-sheet and a larger, mostly α-helical C-terminal lobe (residues 86-298) (Figure 
2.1). The kinase catalytic core is located in a deep cleft between the two lobes of 
CDK2 [81]. Cyclin A binds to one side of this catalytic cleft, interacting with both 
lobes to form a large, continuous protein-protein interface [77].  
 
The activated cyclin A(E)/CDK2 uses its cofactor adenosine triphosphate (ATP) 
together with Mg(II) to phosphorylate serine or threonine residues of its substrates 
(the so-called ‘P’ site) followed by a proline, highly conserved across nearly all 
substrates (at the P+1 site), and a basic residue at the P+3 site [55,82,83]. Structural 
information regarding the key events required for substrate recognition has been 
provided by the crystal structure of the complex between cyclin A/CDK2 bound to the 
HHASPRK peptide (the underlined residues are those recognized by the enzyme), an 
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optimal model peptide substrate [55]. The substrate specificity of CDK2 towards the 
canonical sequence has been defined with respect to the phosphorylation of the model 
peptide substrate. However, some of the in vivo substrates lack the P+3 basic residue, 
and thus do not conform to the optimal consensus sequence as defined by the model 
peptide substrate [83,84].  
 
Structural and biochemical studies on artificial peptide substrates have indicated that a 
hydrophobic binding pocket on the surface of cyclins some 4 nm from the catalytic 
site recruits substrates containing an RXL motif [55,84,85]. The binding of an RXL 
motif is important for making a poor substrate a good substrate, especially when the 
sequence at the site of phosphorylation lacks the P+3 basic residue [85]. Nevertheless, 
it is still unclear whether the structural insight obtained from artificial peptide 
substrates is also true for CDK2’s in vivo substrates.  
 
To investigate this issue, in this thesis I have modeled the binding of CDK2 with two 
in vivo cellular partners, the full-length sirtuin 2 (SIRT2) and p27KIP1 C-terminal 
region using protein-protein docking (see Chapter 5). 
 
2.1.2 p27KIP1 
The CKI p27KIP1 (198 amino acids in full-length) is an intrinsically disordered protein 
(IDP) that regulates cell proliferation through interactions with CDKs and cyclins 
[86]. p27KIP1 inhibits cyclin E and A/CDK complexes thereby blocking the 
progression from G1 into S phase of the cell division cycle [87]. This suggests a role 
of p27KIP1 as tumor suppressor [53]. Correspondingly, many tumors show decreased 
level of p27KIP1 [53]. The protein level of p27KIP1 is controlled by the regulation of 
translation and ubiquitination-dependent degradation, which are further regulated 
through additional post-translational modifications (PTMs) [88]. Indeed, several 
phosphorylation sites on the N-terminal and C-terminal domains of p27KIP1 have been 
recognized (Figure 2.2). 
 
The N-terminal domain of p27KIP1 (residues 1-90) contains a kinase inhibitory domain 
(KID, see Figure 2.2) that is conserved across CKIs [89]. The KID (residues 25 to 90) 
interacts with cyclin and CDK, inhibiting the kinase activity of cyclin/CDK 
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complexes. The crystal structure of p27KIP1-KID bound to cyclin A/CDK2 (Figure 
2.1) has revealed that the KID consists of two binding motifs, i.e. a CDK2-binding 
domain and a cyclin-binding domain [78]. Specifically, the latter interacts with cyclin 
A through the conserved RXL motif.  
 
Phosphorylation at S10 by minibrain-related kinase (MIRK) or kinase interacting 
stathmin (KIS) is considered to be responsible for p27KIP1 export from the nucleus 
[53]. Furthermore, three tyrosine residues, Y74, Y88, and Y89 located at the N-
terminal end of the KID are phosphorylated by Src family kinases (SFKs). These 
tyrosine phosphorylations destabilize the CDK binding of p27KIP1, which therefore 
provides an additional pathway between mitogenic signals and inhibition of the 
function of p27KIP1 as a CKI.  
 
 
Figure 2.2: Schematic of the p27KIP1 domain organization. The N-terminal kinase 
inhibitory domain (KID, residues 28-90) is depicted in orange, the N-terminal 
segment (NTS, residues 1-28) in blue, the C-terminal domain (CT, residues 91-198) 
in red, and the nuclear localization sequence (NLS, residues 152-169) in cyan. The 
phosphorylation sites observed in p27KIP1 are indicated [53]. The cyclin-binding (in 
green) and CDK-binding (in purple) subdomains in KID are highlighted [78]. The 
available crystal structure data for p27KIP1 are highlighted (in black) below, i.e. PDB 
ID: 1JSU [78] (residues 25-93) and 2AST [90] (residues 181-190). The constructed 
structural model of the C-terminal binding region (residues 180-194) in this thesis is 
indicated by the dashed box. 
 
In contrast to the N-terminal region, the C-terminal domain of p27KIP1 (residues 91-
198) does not exhibit any structural or functional similarity to other CKIs [91]. NMR 
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analysis has shown that the p27KIP1 C-terminal domain is highly disordered both in 
isolation and when the KID is bound to the cyclin A/CDK2 [92]. So far, only a short 
segment (residues 181 to 190) of the C-terminal structure has been solved from a 
complex where the p27KIP1 peptide phosphorylated at T187 interacts with the Skp1-
Cul1-Rbx1-F box protein (SCFSKP2) E3 ubiquitin ligase [90]. Indeed, this 
phosphorylation at T187 by CDK1 and CDK2 acts as a signal for the ubiquitination 
and subsequent degradation of p27KIP1 [53]. 
 
2.1.3 SIRT2  
Sirtuin 2 (SIRT2) is one of the seven known human sirtuin proteins. SIRT2 catalyzes 
an NAD+-dependent deacetylase reaction, where one NAD+ is hydrolyzed for one 
acetyl group removed from a substrate. The acetyl group is then transferred to the 
ADP-ribose to form an O-acetyl-ADP-ribose product.  
 
Among the seven human sirtuin proteins, SIRT2 is the only one that is predominantly 
localized in the cytoplasm where it shows a strong colocalization with α-tubulin that 
can be deacetylated by SIRT2 [93,94]. However, SIRT2 can also translocate into the 
nucleus where SIRT2 promotes deacetylation of histone H4 at K16 or histone H3 at 
K56 [95,96]. These modifications correspond to cell-cycle progression or DNA 
damage [95,96]. SIRT2 is highly expressed in brain [97]. Luthi-Carter et al. 
demonstrated that SIRT2 positively regulates the transcription factor sterol response 
element binding protein 2 (SREBP2) to promote cholesterol biosynthesis in neurons 
[46]. Cholesterol is reported to have a detrimental effect in neurons and presents a risk 
factor in neurodegenerative diseases like Alzheimer’s (AD), Huntington’s (HD) and 
Parkinson’s diseases (PD) [47]. Consistently, SIRT2 inhibition reduces toxicity of 
mutant huntingtin by decreasing polyglutamine huntingtin-induced cholesterol 
biosynthesis [46]. Furthermore, SIRT2 knockdown or SIRT2 inhibition decreases α-
synuclein aggregation toxicity, which is a hallmark of the neurodegenerative PD [48]. 
However, the mechanism whereby SIRT2 inhibition affects α-synuclein aggregation 
remains unclear [48]. Beside SIRT2 is also involved in the regulation of other 
transcription factors, such nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB) [49], forkhead box O1 (FOXO1) [50] and FOXO3 [51] to regulate 
multiple cellular processes including inflammation, autophagy and stress response. In 
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this regard, SIRT2 also plays a role in cancer, but it is still debate whether SIRT2 acts 
as a tumor suppressor or oncogene [98]. It was shown that SIRT2 promotes tumor 
formation by decreasing the activity of the tumor suppressor p53 [99]. Consistently, 
exposures of cell to dual inhibitors of SIRT1 and SIRT2 or to selective inhibitors of 
SIRT2 induce apoptosis in some tumor cell lines [100]. In contrast to the role of 
SIRT2 as oncogene, SIRT2 expression is decreased in human glioma, prostate cancer, 
renal cancer and breast cancer, as compared to normal samples [98,101-103]. In line 
with this, SIRT2-deficient mice generated by gene targeting develop tumors in 
multiple tissues [102].  
 
SIRT2 is present in two functionally similar isoforms (isoform 1 and 2, Figure 2.3A). 
Isoform 2 lacks the first 37 N-terminal amino acids compared to isoform 1. Both 
isoforms have the same in vitro and in vivo deacetylation activity [104]. SIRT2 
consists of three domains, i.e. a catalytic core (CC) for NAD+ binding, an N-terminal 
(NT) and a C-terminal (CT) domain (Figure 2.3A). The CC is structured and 
conserved across all sirtuin members (Figure 2.3B) [52,105]. In contrast, the NT and 
CT domains show divergence in length and sequence among sirtuins [106,107]. So 
far, two putative phosphorylation sites have been identified in the SIRT2 CT, i.e. 
S368/331 and S372/335 in isoform 1/2 [108]. S368/331 is located within a CDK 
consensus sequence and can be phosphorylated by CDK1, CDK2, CDK4 and CDK5 
[44,104]. Phosphorylation of SIRT2 at S368/331 reduces its enzymatic activity as 
measured by deacetylation of histones [44]. However, it is still unclear which kinase 
is responsible for the phosphorylation of S372/335 and what its functional role is on 
SIRT2 activity. 
 
In this thesis, I have presented the first full-length molecular models of apo-SIRT2, 
the SIRT2 in complex with NAD+ (SIRT2/NAD+) and the phosphorylated SIRT2 at 
pS331 (SIRT2-pS331) by using bioinformatics tools and molecular dynamics (MD) 
simulations to investigate the intra-molecular regulation mechanisms of SIRT2 
catalytic activity (see Chapter 4). 
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Figure 2.3: Structural features of SIRT2. (A) Primary sequences of human SIRT2 
isoform 1 (SIRT2-iso1) and isoform 2 (SIRT2-iso2) aligned with that of Hst2 from S. 
cerevisiae (obtained with the BLAST webserver 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Identical and structurally similar residues are 
indicated in red and green, respectively. Solid lines indicate the N-terminal (NT, blue) 
and C-terminal (CT, red) regions, and so-called NAD+ cofactor binding loop (green). 
The catalytic center residue H150 (black diamond) and the phosphorylation sites S331 
and S335 (orange diamonds) are indicated. (B) X-ray structure of the catalytic core 
(CC) domain of human SIRT2 (PDB ID: 1J8F [52]). The CC consists of (i) a 
Rossmann fold (orange), made of six β-strands forming a parallel β–sheet and six α-
helices, (ii) a small domain made up by a zinc binding pocket (yellow) and a 
hydrophobic pocket (purple), which contains a three-stranded antiparallel β-sheet 
(yellow), an α-helix (yellow) and a zinc ion (light blue) coordinated by four cysteine 
residues (C195, C200, C221 and C224 (yellow sticks)), and four α-helices forming a 
hydrophobic pocket (red), and (iii) four connecting loops (green). NAD+ is absent in 
the crystal structure. It has been included here by superposing the CC of SIRT2 with 
that of Sir2-Af1 [109], for which a structure with NAD+ is available (NAD+ is in 
magenta). N and C indicate the N-terminal and C-terminal ends of the CC, 
respectively.  
 
2.1.4 Insulin 
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Insulin is a peptide hormone produced by β-cells in the pancreas. Insulin increases 
glucose uptake in muscle and fat by stimulating the translocation of the glucose 
transporter (GLU4) from intracellular sites to the cell surface [110], and inhibits 
hepatic glucose production by promoting hepatic glycogen cycling [111], therefore 
serving as the primary regulator of blood glucose concentration (Figure 2.4). Insulin 
also stimulates cell growth and differentiation, and promotes the storage of substrates 
in fat, liver and muscle by stimulating lipogenesis, glycogen and protein synthesis, 
and inhibiting lipolysis, glycogenolysis and protein digestion [112] (Figure 2.4). 
Thus, insulin resistance or deficiency results in profound dysregulation of these 
processes. As a consequence, insulin is used medically to treat diabetes. Recently, a 
number of epidemiological studies further suggest a link between insulin resistance, 
diabetes and neurodegenerative diseases [113].  
 
The human insulin is composed of two chains from a cleavage of precursor, chain A 
(21 amino acids) and chain B (30 amino acids), which are linked by two disulfide 
bonds. The 3D structure of insulin was ultimately solved in 1969 [114]. Insulin 
monomers aggregate readily to form dimers in solution due to hydrogen bond 
interactions between the two C-terminal regions of chain B. Insulin dimers further 
associate into hexamers in the presence of zinc ions [115]. This pattern of assembly is 
utilized in the biosynthesis, processing and storage of insulin; however, it is the 
insulin monomer that directly binds to its receptor and is responsible for its regulatory 
role [115]. The hexamer-dimer-monomer conversion of insulin (Figure 2.4) has 
important clinical ramifications. The hexamer is far more stable than the monomer 
and dimer; however, the monomer and dimer are much faster-reacting drugs because 
diffusion rate is inversely related to particle size. This phenomenon has stimulated 
development of a number of recombinant insulin analogs (e.g. Lispro [116]) for 
therapeutic aims by modifying the insulin sequence, which does not alter receptor 
binding, but minimizes the tendency to form hexamers or dimers [117]. 
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Figure 2.4: The regulation of metabolism by insulin. Insulin is the most potent 
anabolic hormone known. It promotes the synthesis and storage of carbohydrates, 
lipids and proteins, while inhibiting their degradation and release into the circulation. 
Insulin stimulates the uptake of glucose, amino acids and fatty acids into cells, and 
increases the expression or activity of enzymes that catalyze glycogen, lipid and 
protein synthesis, while inhibiting the activity or expression of those that catalyze 
degradation. Insulin exerts its functions mainly through binding to the insulin 
receptors. Insulin is produced and stored in the body as inactive hexamers and dimers, 
while the active form is the monomer. The 3D structures of insulin hexamer (PDB ID: 
1AIO [118]), dimer (PDB ID: 1MHI [119]) and monomer (PDB ID: 2JV1 [120]) are 
taken from PDB database. The figure is modified from ref. [112]. For the cartoon 
representations of insulin dimer and hexamer, each color code indicates one 
monomer. The zinc ions in the hexamer are presented in gray balls. The chains A and 
B in the insulin monomer are indicated by blue and purple, respectively.  
 
In this thesis, I have used the human insulin dimer as the first test case to investigate 
the applicability of an important assumption for mass spectrometry i.e. that  
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noncovalent protein complexes being transferred into the gas phase preserve basically 
the same intermolecular interactions as in solution (see Chapter 6). 
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Chapter 3 Mass spectrometry in biology  
In this chapter, biological applications and general mechanism of mass spectrometry 
(MS) are summarized. 
3.1 Short history of mass spectrometry  
The basic and unique function performed by MS is to weight molecules through the 
use of electric and magnetic fields [121]. Over the years, a plethora of different MS-
based techniques were developed for different purposes. Today, MS is a common and 
valuable tool widely used in different types of biological research, including structural 
analysis of protein-protein and protein-ligand interactions [122], identification of 
proteins and post-translational modifications [123], proteomics [124], imaging 
[125,126], pharmacokinetics [127,128]. 
 
The MS analysis can be generally represented as several steps. The sample can come 
from different sources, a common one is chromatography, which allows purifying the 
molecules to be analyzed [129]. The compartment is the ion source where the sample 
is ionized (acquiring a net positive or negative charge, depending on the current 
setup) and transferred from liquid or solid crystallized phases to the gas phase 
[130,131]. The ionized molecules fly towards the detector due to a magnetic/electric 
field properly implemented. During the transit towards the mass analyzer, the ions are 
separated according to their mass/charge ratio (m/z) [121]. The detector, where the 
ions end their path, counts the abundance of each single group of ions that share the 
same m/z ratio. The output of a common mass spectrometer measurement is the mass 
spectrum of the sample, where the abundance of different ions (different not only by 
analyte type but also by m/z ratio) is reported. 
 
The application of MS for biological research has been revolutionized over the last 
two decades, as electrospray ionization (ESI) [130] and matrix-assisted laser 
desorption ionization (MALDI) [131] became widely available. Both the inventors 
received the Nobel Prize for Chemistry in 2002 [132]. These “soft” ionization 
techniques enable investigations of a wide variety of biomolecules [133,134]. The 
principal differences between these techniques are the sample preparation and the size 
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of molecules that can be analyzed. MALDI generates ions with a weight limit of a 
few kDa [134]. The ionization process occurs through a laser-induced vaporization of 
the molecule that is crystalized on a solid state matrix. Therefore a drawback of this 
technique is that with increasing molecular size, a more energetic laser beam is 
needed. As a consequence the bond-breaking frequency increases with the generation 
of molecular fragments rather than the entire molecule [135]. On the other hand the 
ESI process starts from a liquid solution and the ionization takes place through a 
gentle evaporation process (Figure 3.1). Therefore, ESI methods are able to maintain 
not only chemical bonds intact, but also noncovalent interactions [67,136]. With 
modern instrumentation, a theoretically unlimited range of molecular weight can be 
analyzed [137,138]. Since in this thesis I applied a molecular simulation-based 
protocol for the structural prediction of protein complexes in ESI-MS, I will focus 
here only on ESI-MS. 
 
 
Figure 3.1: Schematic depiction of an ESI source operated in positive model MS. 
A potential is applied between small needles, which supplies the sample in liquid 
phase. Due to the potential applied, an excess of charge accumulates at the tip of the 
ESI capillary and charged droplets depart. During their flight, the size of the droplets 
decreases due to solvent evaporation. As a consequence, Coulomb repulsion at the 
droplet surface increase, until they overcome the superficial tension of the droplet.  
The figure is adapted from ref. [134]. 
 
3.2 ESI-MS 
The successful applications of ESI-MS for structural biology research rely on the fact 
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that ESI-MS can rapidly and reliably detect proteins and protein complexes formed in 
cellular processes at physiologically relevant concentrations [139,140]. When 
combined with ion mobility (IM)-MS techniques [8,141,142], ESI-MS can provide 
the stoichiometry, topology, connectivity, dynamics and shape of multiprotein 
complexes [8,9,141-144].  
ESI-MS has distinct advantages over quantitative methods such as X-ray 
crystallography and NMR spectroscopy as well as lower resolution techniques such as 
electron microscopy [145] and tomography [146]. Indeed, it does not require 
crystallization and is already sensitive to concentrations well below those required for 
these techniques [9,24,58,147]. Recent advances in MS have led to the first 
measurement of membrane protein complexes [148,149].  
Moreover, the traditional structural biology techniques (e.g. X-ray and NMR) and 
bioinformatics methods (e.g. homology modeling and protein-protein docking) have 
been also coupled with MS-based data sets as a means to predict or verify the 3D 
structures of IDPs and noncovalently bound protein complexes in aqueous solution 
[9,150-158]. 
There are two main observables available from ESI/IM-MS, namely the charge state 
distribution (CSD) and the collision cross section (CCS) [159]. 
3.2.1 Charge state distribution 
CSD is the series of peaks that identify the ions of different m/z ratio generated from 
the ionization process of biomolecular analytes [160,161]. CSD analysis is often used 
in structural biology because it is well known that CSD is associated with the 
conformational features of the molecules in solution [160,162-166]. Indeed, the 
maximum charge state (ZR) determined by the ESI-MS is strongly affected by the 
conformation that the protein holds at the moment of transfer into the gas phase. In 
general, for unfolded proteins, ZR corresponds to the total number of basic residues; 
while for folded proteins, ZR observed is smaller [64].  
Although the conformational factors responsible for protein ionization in ESI-MS are 
not fully understood, it is generally agreed that two conformational features play a 
critical role for CSD [167-172]. These are the solvent accessible surface area (SASA) 
and the apparent gas-phase basicity (GBapp). Both have been related to the protein 
charge states observed under ESI conditions [167-173].  
Canonical relation for folded proteins exists between average charge state of CSD 
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(Zave) and SASA calculated on crystallographic or NMR structures [167-170]. Similar 
relation has been shown to hold also for unfolded proteins [169], in which the average 
SASA values were computed on sampled structures obtained from the Monte-Carlo-
based ProtSA server [174]. Therefore, the CSD analysis can be used for the 
estimation of protein structural parameters (e.g. SASA), which can lead to high-
resolution structural prediction by performing restrained molecular modeling 
[175,176]. 
GB measures the propensity of acquiring a proton under vanishing-solvent conditions, 
which is essential to interpret proton-transfer reactions occurred during ESI [177]. In 
the case of proteins, the tabulated values of intrinsic GB for ionizable residues need to 
be corrected accounting for intramolecular interactions and, thus, yielding the 
conformation-dependent parameter, GBapp [178-180]. It has been shown that the 
calculated GBapp of a protein in its ZR, taking into account the contributions from 
intra-molecular interactions and conformational changes around charge site, 
approaches the GB of the solvent used for sample infusion [171]. It holds for both 
folded and unfolded proteins [171,172]. Such relation has been successfully used for 
the validation of molecular models obtained from gas-phase simulations [172]. It has 
been also used for the same purpose in this thesis (Chapter 6). 
3.2.2 CCS 
An increasingly common approach to the structural characterization of gas-phase 
proteins and protein complexes is ESI/IM-MS [181]. In ESI/IM-MS experiments, 
protein ions move through a neutral drift gas, typically helium or nitrogen, under the 
influence of a weak electric field. By measuring the drift velocity (vd) of an ion 
through such a drift field and the relationship between vd and mobility (K),2 it is 
possible to determine its CCS according to the following equation [141]: 
     (3.1) 
where z is the ion charge state, e is the elementary charge, N is the gas number 
density, µ is the reduced mass of the ion-neutral gas pair, kB is the Boltzmann 
constant, T is the gas temperature and Ω is the CCS to be determined. This 
                                                
2vd = KE, where E is the electric field [141]. 
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experimental CCS (Ω) which is buffer gas dependent [182] can be compared to cross 
sections derived from coordinates obtained from other structural biology methods (for 
example NMR or X-ray), or from computational predictions, to obtain high-resolution 
(e.g. atomistic level) conformational information [141]. In these theoretical 
calculations of CCS, it is presumed that at week electric fields in IM, ions experience 
free rotation [181]. Hence, mobility calculations involve averaging of the ion-neutral 
gas cross-sections over all collision geometries. The orientational averaging is given 
as: 
  (3.2) 
where θ, ϕ and γ are spatial angles defining the ion orientation and ΩP is the 
corresponding partial cross-section that depends on the model for ion-neutral gas 
interaction. In the widely used projection approximation (PA) method [183]: 
   (3.3) 
where b is the impact parameter and M is unity when a hard-sphere collision occurs 
for the configuration defined by θ, ϕ, γ and b, and null otherwise. However, in this 
implementation, the integrand is not defined via a radial coordinate b, but via 
cartesian coordinates inside a rectangle (with sides along y and z) drawn around the 
projection of an ion onto the yz plane [183-185]. Averaging over those coordinates 
produces a directional cross-section Ωdir: 
    (3.4) 
Eq. (3.4) was convoluted with Eq. (3.2) using Monte Carlo (MC) integration, by 
shooting a certain number of gas molecules at the ion along a selected axis (e.g. x) 
and counting hits. In the most widely used code MOBCAL [184,185] (also applied in 
this thesis), the ion is rotated around all three axes by random θ, ϕ and γ before each 
shot. 
3.2.3 Remarks 
There is an intense debate concerning comparison of solution and gas-phase protein 
structures [141]. Indeed, a large extent of the theoretical investigations of charge state 
and CCS have been carried out using the structures derived from the NMR or X-ray 
structures or using molecular simulations in solution, where it is assumed that the ESI 
process itself does not significantly perturb protein structure [186,187]. However, 
  
Ω =
1
8π 2 dθ0
2π∫ dϕsinϕ0
π∫ dγ0
2π∫ ΩP θ,ϕ,γ( )
  
ΩP θ,ϕ,γ( ) = 2π bM0
∞∫ θ,ϕ,γ( )db
  
Ωdir ϕ,γ( ) = M−∞
+∞∫ ϕ,γ ,y,z( )dydz−∞
+∞∫
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experimental approaches are very limited in this regard, because of the difficulty to 
solve gas-phase protein structures at high resolution. Therefore, in the last decades, an 
increasing number of theoretical works have been carried out to elucidate this relevant 
and crucial matter by developing models of proteins and peptides under ESI 
conditions [63,68,186,188-209]. In this thesis, I have investigated this highly debated 
assumption by extending an in-house protocol [68] (see Chapter 8 for detailed 
methodology) for structural prediction of single proteins in ESI-MS to protein 
complexes (Chapter 6). I have applied the protocol to the human insulin dimer as a 
test case. The calculations have been validated by reproducing experimental charge 
state and CCS. The structural determinants and inter-molecular interaction patterns 
have been compared between solution and gas phase. 
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Chapter 4 Interaction between CDK2's and its cellular partners 
investigated by computational methods  
 
3.1 Introduction 
The interaction of human cyclin-dependent kinase 2 (CDK2), in association with 
cyclin A or cyclin E (cyclin A(E)/CDK2) [210], regulates cell proliferation [31,32]. 
Cyclin A(E)/CDK2 is a promising target for pharmaceutical interventions [211-214]. 
The phosphorylation by cyclin A(E)/CDK2 of its substrates is involved in 
neurodegenerative disorders, cardiovascular diseases, viral inflection, cancer and 
alopecia [33-44].  
 
Cyclin A(E)/CDK2 uses its cofactor adenosine triphosphate (ATP) to phosphorylate 
serine or threonine residues of its substrates (the so-called ‘P’ site) followed by a 
highly conserved proline (the P+1 site), and a basic residue at the P+3 site [55,82,83]. 
Structural information of CDK-substrate interaction has been provided by solving the 
complex between CDK2 and cyclin A bound to the HHASPRK peptide (the 
underlined residues are those recognized by the enzyme) [55]. Here, S4 forms a 
hydrogen bond with ATP (Figure 4.1). P5 forms hydrophobic contacts with V163 in 
CDK2 and V164 in CDK2. K7 forms a salt bridge with a phosphorylated T160 in 
CDK2 (pT160) and a hydrogen bond with I270 in cyclin A. 
 
A key issue for drug design is of course whether CDK2’s cellular partners share a 
similar binding mode3 as that of this model complex or whether the presence of a 
longer polypeptide chain in real proteins affects the binding. Here we address this 
issue by using a variety of computational methods. We focus on the p27KIP1 [215] and 
sirtuin 2 (SIRT2) proteins [44,216-218], whose cyclin A(E)/CDK2-induced 
phosphorylation contributes their functions and is suggested to be associated with 
diseases [44,216,219].  
 
                                                
3Sequence logo analysis for CDK2 in vivo substrates (Figure A2) indicates 61.9% of these 
substrates fulfill the consensus sequence.  
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Figure 4.1: Cyclin A/CDK2•HHASPRK X-ray structure (PDB ID: 1QMZ [55]). 
(A) Cartoon representation of the whole complex. (B) Close-up view of CDK2 active 
site. The cartoon representations of CDK2, cyclin A, and peptide substrate are colored 
in blue, orange, and green, respectively. Hydrogen bonds are highlighted in black 
broken lines. The Mg(II) ion and coordinated water molecule are represented by green 
and red spheres, respectively.  
 
There are two main strategies for structural predictions of protein complexes [220]. 
Template-based docking is a high-throughput method, which performs fairly well 
when using with high- and medium-sequence or structural similarity (root-mean-
square deviation, RMSD <6 Å) between the template and target [220]. This is not the 
case here as the peptide in the only available crystal structure of a cyclin 
A/CDK2/substrate complex is not large enough to provide the whole information on 
the protein-protein interface for template-based docking [55]. Free Docking is then 
the method of choice. It consists in docking the interacting proteins using the 
available experimental constraints. In our case, the recognition regions of p27KIP1 and 
SIRT2 are disordered and no structural information is available for the whole region4. 
Hence, we have used homology and ab initio modeling along with existing structural 
information [52,55,90] to construct structural models of the interactors. These are the 
full-length SIRT2 (see Chapter 5 for the model construction) and a p27KIP1 C-terminal 
peptide, which is longer than the peptide studied so far in ref. [55]. The docking is 
guided by two key observations. First, substrate's phosphorylatable serine/threonine 
(P site) forms a H-bond with ATP [55]. Second, substrate's basic residue at the P+3 
                                                
4The occurrence of disordered regions for kinases substrates is common, since kinases 
normally phosphorylate sites in less ordered and exposed on surface parts [221-224]. 
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site form H-bonds to CDK2's pT160 and cyclin A’s I270 [55,225]. We find that these 
substrates with the same consensus sequence display a similar mode of binding on the 
CDK2. This corroborates the utility of using experimental structural information from 
the model complex in ref. [55] as template for ligands interfering with cyclin 
A/CDK2 binding to substrates in diseases. 
 
4.2 Results and discussion 
In this section, first we described our structural models for the interacting proteins and 
then we turn our attention to the formed complexes. 
 
Cyclin A/CDK2 features in vivo either one Mg(II) ion (as in the X-ray structure of 
cyclin A/CDK2•HHASPRK [55], model A) or two Mg(II) ions (model B) [226,227]. 
In A, the Mg(II) ion is coordinated by N132 and D145 of CDK2, ATP and one water 
molecule (Figure 4.1B), and the cofactors (ATP and Mg(II)) bind in the interface 
between a small N-terminal lobe and a larger C-terminal lobe of CDK2 [228]. In B, 
one Mg(II) is located as in the X-ray structure [55] whilst the second ion binds to 
D145 (highly conserved across the kinase superfamily [229]), ATP and two water 
molecules (Figure 4.2). 
 
 
 
Figure 4.2: Structures of PKA (A, PDB ID: 1ATP [230]) and CDK2 (B) in 
complex with ATP and two metals, as obtained by computational methods in this 
work. The Mn(II) and Mg(II) are colored in purple and green, respectively. The 
coordinated water molecules are represented by red spheres.  
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SIRT2 contains a structured domain (residues 26-319), for which structural 
information is available [30] and two unstructured regions, the N-terminal and C-
terminal (residues 1-25 and 320-352, respectively). The recognized sequence by 
CDK2 is located at the C-terminal residue S331 (331SPKK334). Structural models of 
both are obtained by ab initio and homology modeling, followed by MD simulations 
in water (see Chapter 5).  
 
Full-length p27KIP1 (198 residues) is a naturally unfolded protein [86]. Determining its 
conformations based on computational method is presently very challenging. Here we 
restrict ourselves to the binding region of the protein. p27KIP1 binds to cyclin A/CDK2 
in two regions. The phosphorylation of residues Y88 by non-receptor tyrosine kinases 
(NRTKs) in the N-terminal binding region [231,232] (residues 78-90, 
EVEKGSLPEFYYR) triggers a conformational transition of cyclin A/CDK2 [92]. 
This in turn promotes the binding of the C-terminal region and its subsequent CDK2-
mediated phosphorylation at T187 (residues 187TPKK190 ) [232]. Here we construct 
structural models of the cyclin A/CDK2 binding region at the C-terminal region 
(residues 180-194, see Figure 2.2). 
 
As the number of Mg(II) coordinated with CDK2 in vivo is still unclear [226], two 
models of human cyclin A/CDK2 in complex with different numbers of Mg(II) were 
constructed (A and B hereafter). A is based on the X-ray structure of human CDK2 in 
complex with cyclin A (PDB ID: 1QMZ [55]). This contains one Mg(II) ion bound to 
a water molecule, the ATP cofactor, N132 and D145 of CDK2. B contains two Mg(II) 
ions, as this specie could be present in vivo [226]. To construct the model of it, we 
superimposed CDK2 crystal structure with the X-ray structure of protein kinase A 
(PKA, PDB ID: 1ATP [230]), which contains two metal ions (Mn(II)) and 
coordinated water molecules. This procedure follows the same protocol used in ref. 
[226] (see Appendix A2.1). We dock A and B onto the HHASPRK peptide, the 
p27KIP1 fragment and the full-length SIRT2. We introduce distance constrains 
between the P site and ATP and between the P+3 site and pT160 of CDK2 and I270 
of cyclin A (Figure 4.3). We use the HADDOCK program [233,234]. In all 
circumstances, adducts with A turned out to feature better HADDOCK scoring, 
number of best-scoring structures, and distance between ATP and the residues at P 
site, than those of B (data not shown). Therefore, the adducts with A are those 
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discussed here. 
 
 
Figure 4.3: Schematic overview of the restraints applied between the cyclin 
A/CDK2 complex and substrates in protein-protein docking.  
 
 
 
Figure 4.4: The cyclin A/CDK2•SIRT2 complex as obtained in this work. (A) 
Cartoon representation of the overall complex. (B) Close-up view of the binding 
interface between SIRT2 and cyclin A/CDK2. The cartoon representations of CDK2, 
cyclin A, and SIRT2 are colored in blue, orange, and green, respectively.  Hydrogen 
bonds are highlighted in black broken lines.  
 
Our structural model of cyclin A/CDK2•HHASPRK (Figure A4) is similar to the X-
ray structure (backbone RMSD 0.5 Å). The docking model reproduces the contacts 
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between cyclin A/CDK2 and peptide substrate as observed in crystal structures [55], 
summarized in Figure 4.1. However, the coordination distances between Mg(II) and 
oxygen atoms of ligands are slightly changed: those distances range from 1.4 Å to 2.2 
Å measured from the docking structure (Figure A5), while the ones measured from 
crystal structures range from 1.9 Å to 2.2 Å with an average of around 2.1 Å [55]. 
 
In the cyclin A/CDK2•SIRT2 complex, S331 forms a hydrogen bond with ATP at the 
P site. K334 at the P+3 site forms a salt bridge with pT160 in CDK2 and an H-bond 
with I270 from cyclin A (Figure 4.4). P332 (P+1 site) interacts with V163 and V164 
in the activation loop in CDK2 and both of the two valines maintain left-handed 
conformations. The above described interaction patterns of the consensus sequences 
are very similar to those obtained from the X-ray structure with HHASPRK [55] and 
the RMSD of the backbone in the recognized sequences in the two complexes is as 
low as 0.3 Å.  
 
Besides the contacts in the consensus sequence, we find a variety of additional 
contacts between SIRT2 and CDK2. Specifically C-terminal residue T328 in SIRT2 
forms hydrogen bond with D206 in CDK2 backbone. Hence, the C-terminal region in 
SIRT2 may regulate the interaction of SIRT2 with CDK2. This suggests that the C-
terminal region may be involved in the recognition of substrates by SIRT2 and 
possibly other sirtuins. This hypothesis is supported by the fact that a majority of 
sirtuins’ post-translational modifications (including phosphorylation, sumoylation and 
acetylation) occurs within the C-terminal region [44,107,108,235-237]. Moreover, the 
cofactor binding loop in SIRT2 (CBL, residues 55-80), highly conserved across 
sirtuins (sequence identities ranging from 46% to 75% [238]), may serve as regulator 
between SIRT2 and CDK2. Indeed H74 at CBL forms an H-bond with E12 near the 
glycine-rich loop in CDK2 (G-loop, residues 10-18). This corroborates the previous 
hypothesis that the highly dynamic CBL loop may be involved in protein-protein 
interactions between sirtuins and their cellular partners [109]. Indeed, the CBL adopts 
a variety of configurations in different crystal structures of sirtuins [239-242]. For 
instance, the comparison between the monoclinic and orthorhombic crystal structures 
of Sir2-Af1 from A. fulgidus (sequence identity with SIRT2 in the CC is 26%) shows 
significant differences in the CBL region, i.e. the CBL in orthorhombic structure is 
 31 
about 4 Å away from its respective position in monoclinic structure [109]. 
Furthermore, the CBL presents high diversity of secondary structures (observed in the 
crystal structures of SIRT3 [243] and SIRT5 [244]), which may facility its structural 
transition to fit different protein partners. The Mg(II) in the cyclin A/CDK2•SIRT2 
model interacts with ATP, D145 and N132 of CDK2 (Figure A5). However slightly 
differences are observed for the position of Mg(II) in our docking model, with respect 
to the ones of the X-ray structure [55], i.e. the distances between Mg(II) and ligands 
ranging from 1.4 Å to 2.2 Å measured from the docking structure, while the ones 
measured from crystal structures range from 1.9 Å to 2.2 Å. 
 
 
 
Figure 4.5: Structural model of CDK2/p27KIP1 complex. (A) Cartoon 
representation of the overall structure. The cartoon representations of CDK2, cyclin 
A, and p27KIP1 are colored in blue, orange, and green, respectively. (B) Close-up view 
of the binding interface between p27KIP1 and cyclin A/CDK2. Hydrogen bonds are 
highlighted in black broken lines.  
 
The p27KIP1 peptide adopts an extended conformation in CDK2's active site (Figure 
4.5). For the consensus sequence region of p27KIP1, the same interaction patterns are 
observed as that of the crystal structure of cyclin A/CDK2•HHASPRK [55], i.e. T187 
forms an H-bond with ATP in the P site, and K190 in the P+3 site forms a salt bridge 
with pT160 in CDK2, and forms an H-bond with I270 in cyclin A. In the crystal 
structure [55], the arginine at the non-conserved P+2 site does not form any contact 
with cyclin A/CDK2. On the contrary, the lysine at P+2 site of p27KIP1 (K188) forms 
a salt bridge with ATP and an H-bond with T14 in CDK2 (Figure 4.3B). Interestingly, 
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the location of the positive side chain nitrogen of K188 in p27KIP1 is similar to the 
second metal ion as observed in the PKA crystal structure and our constructed 
2Mg(II) model (Figure A8), which suggests that the lysine at P+2 site in p27KIP1 
might function as endogenous counter-ion. This functional role of lysine has been 
demonstrated in the H+/K+ and Na+/K+ ATPases, which use the basic lysine residues 
instead a proton or a sodium [245,246]. This differs from SIRT2 where the P+2 site 
lysine (K333) makes salt bridge with E71 of the CBL. Some other additional contacts 
were also identified between the non-consensus part of p27KIP1 and cyclin A/CDK2. 
S183 and G182 make hydrogen bonds with active site residues, Q131 and K88 of 
CDK2, respectively (Figure 4.3B). Furthermore, R194 forms hydrogen bonds with 
E42 in CDK2 and P272 in cyclin A located in the CDK2/cyclin A interface. E42 in 
CDK2, conserved across CDK2, CDK3, CDK5 and CDK6 [247], belongs to the 
extension loop of PSTAIRE helix in CDK2 (residues 45-51), which has the most 
significant movement upon cyclin A binding [77]. Together with two other acidic 
residues (D38 and E40), it is believed that they may interact with the basic arginine 
residues (R556 and R562) of the C-terminal tail of Cdc25B5 [249].  
 
The Mg(II) in the cyclin A/CDK2•p27KIP1 model interacts with ATP, D145 and N132 
of CDK2 (Figure A7). However differences are observed for the position of Mg(II) in 
our docking model, with respect to the ones of the X-ray structure [55], i.e. the 
distances between Mg(II) and ligands ranging from 1.3 Å to 3.0 Å measured from the 
docking structure, while the ones measured from crystal structures range from 1.9 Å 
to 2.2 Å. 
4.3 Conclusions 
Our findings suggest that in vivo substrates with the same consensus sequence display 
a similar mode of binding on the CDK2. Hence the identified structural determinants 
of such interactions can be fruitfully used as templates for drug-design approaches. 
4.4 Methods  
Based on the X-ray structure of part of human SIRT2 (PDB ID: 1J8F [52]), the full-
length SIRT2 model was constructed by using structural bioinformatics and MD 
simulations (see details in Chapter 5).  
                                                
5Cyclin A/CDK2 is activated in early G2 phase by phosphatase Cdc25B [248]. 
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The structural prediction of p27KIP1 is currently challenging. This is mainly due to the 
fact that full-length p27KIP1 (198 amino acids) is largely disordered in solution as 
indicated by circular dichroism (CD) spectroscopy [250].  No structural information is 
present for the intrinsically disordered 100 residues of the p27KIP1 C-terminal domain 
(residues 91-198) [251].  Such information is instead available for the kinase 
inhibitory domain (KID, residues 28-90), which is partially structured: its binary 
complex crystal structure with cyclin A/CDK2 is available [78]. Here we constructed 
models of C-terminal p27KIP1 peptide (residues 180-194, sequence 
NAGSVEQTPKKPGLR) based on 181AGSVEQTPKK190 peptide X-ray structure 
(PDB ID: 2AST [90]). We used the MODELLER 9v9 package [252]. The X-ray 
structure of 30S ribosomal protein S8 [253] (residues 81-85, sequence KPGLR) was 
selected as the template to model the missing four residues in C-terminal (see 
Appendix A2.2). 
 
Docking. A and B were docked onto the HHASPRK peptide, p27KIP1 and SIRT2. We 
considered only non-hydrogen atoms. We imposed restraints between substrate's P 
site residue and ATP, because the contact between ATP and the P site residue is the 
prerequisite for the phosphoryl group transfer reaction [254], and between substrate's 
basic residue at P+3 site and CDK2's pT160 and cyclin A’s I270, because these 
contacts are crucial for the specificity of the substrate at P+3 position, as indicated by 
the crystal structure of cyclin A/CDK2•HHASPRK [55]. Distance restraints [234] 
were applied on Mg(II) ions and their ligands to preserve the coordination structure. 
The HADDOCK (High Ambiguity Driven protein-protein Docking) [233,234] 
program was used. Rigid body docking, semi-flexible simulated annealing and water 
MD refinement were carried out. The Appendix A2 reports details for many of the 
calculations presented here. 
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Chapter 5 Insight into the mechanism of intramolecular inhibition of 
the catalytic activity of sirtuin 2 
5.1 Introduction 
The human nicotinamide adenine dinucleotide (NAD+)-dependent enzyme Sir2-like 
protein 2 (352 amino acids6) (SIRT2 hereafter, Figure 2.2) has been associated with 
several age-related diseases, including diabetes, cardiovascular diseases, 
neurodegenerative disorders and cancer [46,48,216,257,258]. Hence, targeting SIRT2 
may be of therapeutic relevance. SIRT2 deacetylates lysine residues in a variety of 
target proteins, thus antagonizing acetyltransferases [217,218]. Inhibitors of the 
catalytic activity of SIRT2 have been shown to interfere with α-synuclein toxicity 
[48], which is associated with neurodegeneration in Parkinson’s disease, and with 
tumorigenesis [216]. However these inhibitors are non-selective as they bind also to 
other members of the sirtuin family [48,259,260].  
 
Previously we found that cyclin-dependent kinase 2 (CDK2) and CDK5 can 
phosphorylate SIRT2 at serine (S) 331 in isoform 2 (S368 in isoform 1). This serine 
residue is located within the naturally disordered C-terminal region (CT, residues 
320-352 in isoform 2). This phosphorylation inhibits the enzymatic activity of SIRT2 
both in vitro and in cells [44]. Along with our findings, North and co-workers found 
that SIRT2 is also a target for CDK1, and its phosphorylation at S331 is required for 
SIRT2 to mediate a delay in cellular proliferation [104]. Hence, the CT might be a 
regulatory domain to control SIRT2 activity. In an effort to establish whether this is 
indeed the case, we have used bioinformatics tools and molecular dynamics (MD) 
simulations to provide molecular models of the full-length protein, without and with 
the NAD+ cofactor (SIRT2 and SIRT2/NAD+, respectively, hereafter), as well as with 
a phosphorylated S331 without NAD+ (SIRT2-pS331 hereafter). The predictions are 
                                                
6SIRT2 is present in two functionally similar isoforms (isoform 1 and 2). Isoform 2 lacks the 
first 37 N-terminal amino acids compared to isoform 1. Both isoforms have the same in vitro 
and in vivo deacetylation activity [104]. In the current study, we focus on isoform 2 of SIRT2, 
which for example is the isoform that presents in the myelin-enriched fractions of adult 
mouse brains and in the cytoplasm of murine cerebellar granule cells [255,256]. 
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based on the structured catalytic core (CC, residues 26-319 in isoform 2) deduced 
from the crystal structure [52]. The calculations are complemented by enzymatic 
essays from Prof. Lüscher’s Lab. Our in silico and in vitro approaches provide a 
consistent picture based on which we suggest that the CT functions as an 
autoinhibitory region by partially occluding the NAD+ binding site in SIRT2 or 
stabilizing the NAD+ in a non-productive state in SIRT2/NAD+. This occlusion is 
increased by phosphorylation at S331. 
5.2 Results and discussion 
The two major SIRT2 isoforms 1 and 2 with 389 and 352 amino acids, respectively, 
consist of three domains, i.e. the catalytic core domain (CC), an N-terminal (NT) and 
a C-terminal (CT) domain (Figure 2.2A). The CC is structured and conserved across 
all sirtuin members [105]. It contains a large, structurally homologous Rossmann fold 
(the so-called large domain [52]), a small, structurally diverse domain (the so-called 
small domain [52]) made up by a zinc binding pocket and a hydrophobic pocket, and 
four loops connecting the two domains (see Figure 2.2B). On the other hand, the NT 
and CT show divergence in length and sequence among sirtuins [106,107]. They are 
disordered and are presumed to be highly flexible [105]. In the isoform 2 of SIRT2, 
modeled in this work, NT and CT are composed of amino acids 1-25 and 320-352, 
respectively. 
 
In the following paragraphs, I will first describe our models of full-length SIRT2 with 
and without NAD+ showing how the presence of the CT tail may affect the CC of the 
protein. Then we discuss the model of SIRT2 which is phosphorylated. Specifically 
we show how phosphorylation of the CT might interfere with SIRT2 function by 
modifying the interaction of the CT with the NAD+ binding site.  
 
SIRT2. Full-length models of wild-type SIRT2 with and without NAD+ were 
obtained by combining bioinformatics, modeling techniques and MD simulations. The 
stability, sampling and convergence of our MD simulations were established by 
calculating the backbone RMSD and by performing principal component (PC) 
analysis. The RMSD values for backbone atoms of CC in both systems oscillate 
around 2 Å compared to the X-ray structure [52]. The NT and CT regions, as 
expected, have much larger RMSD. The RMSD values of NT and CT reach a plateau 
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after around 130 ns and 80 ns in the SIRT2/NAD+ and SIRT2 MD simulations, 
respectively (data not shown). The sampling and convergence of our MD simulations 
were further checked by performing the PC analysis and calculating the cosine 
contents of the dominant PCs, following the procedures presented in ref. [261]. The 
cosine contents for both systems are small, i.e. 0.022, 0.002 and 0.131 for the first 
three PCs in SIRT2/NAD+, and 0.037, 0.036, and 0.116 for the first three PCs in 
SIRT2. These small values (close to 0) indicate good sampling and convergence of 
our simulations [261]. In the following, we will describe the structural features of our 
models for each domain.  
 
 
Figure 5.1: Structural comparison of the CC domain obtained from X-ray 
structure determinations and of the modeled SIRT2/NAD+ complex, the modeled 
SIRT2 and the modeled SIRT2-pS331. The CC crystal structure and our models are 
colored in gray and green, respectively. The NT and CT are colored in blue and pink, 
respectively. The NAD+ cofactor in the CC of the modeled SIRT2/NAD+ is 
represented by orange sticks. 
 
The model structures show a conserved CC domain highly similar to the X-ray 
structure [52] (RMSD values are 0.22±0.02 nm and 0.26±0.02 nm for SIRT2/NAD+ 
and SIRT2, respectively), a structurally variable and partially disordered NT, while 
the presence of a short helical region is predicted for CT (Figure 5.1).  
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Figure 5.2: NAD+ binding site in full-length SIRT2. (A) Overall view of the 
SIRT2/NAD+ complex. The NAD+ (yellow) and catalytic residue H150 (green) are 
represented by sticks. The CT is highlighted in pink. The sites A, B and C of SIRT2, 
which are involved in NAD+ binding, are indicated by blue circles. (B) Close-up view 
of the binding site of nicotinamide and nicotinamide ribose. (C) Close-up view of the 
binding site of adenine. Hydrogen bonds are highlighted in dashed lines. (D) 
Superposition of two crystal structures of Sir2-Af2/NAD+ (PDB ID: 1S7G [262]) with 
the SIRT2/NAD+ complex (in green). The chain A (NAD+ in non-productive 
conformation) and chain B (NAD+ in productive conformation) of 1S7G are colored 
in blue and salmon, respectively. The NAD+ cofactors are represented by sticks. 
 
The NT tail. The NT extension is located below the large domain of CC in both the 
SIRT2/NAD+ and the SIRT2 models, far away from the active site (Figure 5.1). This 
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suggests that the NT does neither influence NAD+ nor substrate binding. Consistently 
the NT has no effect on the in vitro deacetylase activity of SIRT2 [52]. 
 
The CC domain. In the X-ray structures of the CC domain of sirtuins 
[105,109,238,262,263], the CC hosts the NAD+ cofactor required for enzymatic 
activity. The NAD+ binding pocket is located across a Rossmann fold and a 
hydrophobic pocket (Figure 5.2A-2C). The NAD+ binding pocket can be divided into 
three regions (A, B and C sites) [109]: site A, where the adenine ribose moiety of 
NAD+ is bound; site B, where the nicotinamide ribose of NAD+ is bound; and site C, 
where the nicotinamide moiety of NAD+ is bound. The location of nicotinamide 
characterizes a productive or a non-productive state for NAD+ [105,262,263] (Figure 
5.2D). In the first, the nicotinamide ribose is hydrogen bonded with the acetyl-lysine 
carbonyl oxygen of the substrate, which would allow the nucleophilic attack on the 
nicotinamide ribose for the deacetylation catalysis [105,262,263]. In the second 
[109,238,262], NAD+ is located out of site C (Figure 5.2A). As a result, the 
nicotinamide moiety of NAD+ fails to interact with key residues required for catalysis 
and the complex is not productive. 
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Figure 5.3: Interaction of the CT region with the NAD+ binding site. (A) Detailed 
view of the interactions between the CC and the CT in the SIRT2 model. The CC, 
NT, CTL and CTH are colored in green, blue, yellow and pink, respectively. The 
hydrogen bonds are represented by dashed lines. The details of the labeled hydrogen 
bonds and salt bridges are shown in Table 5.2. CTL and CTH refer to the C-terminal 
loop and α-helix, respectively. (B) Superposition of the most representative 
configurations of SIRT2/NAD+ (cyan) and SIRT2 (green). The CT of SIRT2 model is 
colored in pink. The NAD+ cofactor in the SIRT2/NAD+ is represented by yellow 
sticks. See Table 5.1 for the definition of the measured atomic distances (d1, d2, d3 
and d4). The two arrows from T346 and E349 refer to the two positions of these 
amino acids in the SIRT2 and the SIRT2/NAD+ models. 
 
Both full-length proteins without and with NAD+ are, not unexpectedly, 
architecturally similar to the previously reported CC crystal structure (Figure 5.1). 
However, the insertion loop consisting of L21-α12-L22 (residues 250-280) along with 
the α11 helix (residues 230-236), and the cofactor binding loop L4-α3-L5 (residues 
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55-80, one of the most conserved regions of sirtuins [239-242]), rearrange 
considerably in the presence of the CT because of multiple interactions (Figure 5.3A). 
This is of special importance, as they may play a role in NAD+ binding and substrate 
recognition [52]. In particular, the insertion loop has been suggested to be important 
for substrate selection [52,264]. Thus the CT is likely to contribute, indirectly, to 
NAD+ binding and substrate specificity. 
 
In our SIRT2/NAD+ model, NAD+ is bound in a non-productive state (Figure 5.2A). 
It binds to a large groove between the Rossmann fold and the hydrophobic pocket of 
the smaller domain (Figure 5.2A), similar to the previously reported structures of 
sirtuins/NAD+ [105,109,238,262,263]. In this conformation the nicotinamide moiety 
of NAD+ forms hydrophobic contacts with Q130, H150 and V229 around the active 
site (Figure 5.2B)7. The nicotinamide ribose in site B forms two hydrogen bonds with 
CC residues, R60 with the oxygen of the ribose ring and Q228 with the hydroxyl 
group at position 2′′, and a hydrogen bond between E349 of the CT and the hydroxyl 
group at position 3′′, (Figure 5.2B). The adenine base (bound to site A) sits in a 
partially hydrophobic pocket. It forms several hydrogen bonds with the side chains of 
T52, S53, C287 and the highly conserved N249 (93% of conservation across all 
sirtuin members in all species [105]), and with K250 and C287 backbone atoms 
(Figure 5.2C). The partially conserved E2518 makes hydrogen bonds with both OH 
groups of the adenine ribose, and is salt bridged with a CT residue, K350. The oxygen 
atoms of the phosphate groups that connect the two ribose groups make several 
hydrogen bonds with Q130, S226 and Q228 (Figure 5.2C). 
 
The CT tail. The CT in both our predicted wild-type full-length models, i.e. with or 
without NAD+ (Figure 5.1), contains a short helix (CTH hereafter, residues T345-
K350) and a longer disordered loop (CTL hereafter, residues G320-R344) connecting 
                                                
7Such weak interactions between nicotinamide and SIRT2 imply a larger conformational 
flexibility of nicotinamide in the substrate-free SIRT2, consistent with the variability of the 
nicotinamide binding position observed in previously solved crystal structures [109,238,262]. 
Such flexibility may ease the passing of NAD+ from the non-productive to the productive 
state, accompanied with the rotation of the nicotinamide (shift from hydrophobic pocket to 
interacting with site C) and nicotinamide ribose (bound to site B) of NAD+ in the presence of 
substrates [265]. 
8It is conserved among SIRT1, SIRT2, SIRT5, Sir2-Af2 from A. fulgidus and homologous to 
Sir2 protein 2 (Hst2) from yeast (36% of conservation). 
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the CTH with the CC (Figure 5.3A). CTL adapts a turn conformation around the L4-
α3 of the CC, making extensive interactions with the cofactor binding loop and the 
α9 of the zinc-binding domain (Figure 5.3A). CTH binds at the edge of the 
nicotinamide ribose-binding site (site B) between the large Rossmann fold and the 
hydrophobic pocket in the small domain (Figure 5.3A) in both our predicted wild-type 
models. However, CTH is locked deeper into the active site of SIRT2 than 
SIRT2/NAD+, because T346 in CTH occupies the binding site of the hydroxyl groups 
of NAD+ nicotinamide ribose (Figure 5.3B). In particular, the Cα distances between 
T346 and H150, Q130, and V229 of the CC decrease about 0.2 nm (see Table 5.1) in 
SIRT2 with respect to SIRT2/NAD+. Furthermore CTH residue E349 forms a salt 
bridge with R60 in the cofactor binding loop. This stabilizes the interaction of the 
CTH with the active center in the absence of NAD+. Therefore, the SIRT2 CT may 
function as an autoinhibitory region to regulate the deacetylation activity by partially 
occluding the binding site of NAD+, and therefore decreasing its binding affinity for 
NAD+. 
 
Table 5.1: Average atomic distances (in nm) between Cα  of T346 and that of 
H150, Q130 and Q229, and between Cς  of R60 and C of E349. The standard 
deviations are also reported. 
 
 Atomic distances SIRT2/NAD+ SIRT2 SIRT2-pS331 
d1 Cα of H150 - Cα of T346 1.55 (0.19) 1.35 (0.08) 1.23 (0.09) 
d2 Cα of Q130 - Cα of T346 1.42 (0.18) 1.21 (0.08) 1.10 (0.11) 
d3 Cα of V229 - Cα of T346 1.19 (0.10) 0.86 (0.09) 0.66 (0.08) 
d4 Cς of R60 - Cδ of E349 0.71 (0.23) 0.45 (0.15) 1.34 (0.46) 
 
In SIRT2/NAD+ the E349 of the CT forms hydrogen bond interactions with the 
nicotinamide ribose. This may increase the energy barrier of NAD+ for passing from 
the non-productive to the active productive state, which is unfavorable for trigging the 
following deacetylation reaction.  
 
We tested the hypothesis that the CT of SIRT2 has an autoinhibitory function by 
measuring the catalytic activity of full-length SIRT2 and of SIRT2 with a deletion of 
the CT using GST fusion proteins. We incubated GST-SIRT2, C-terminally truncated 
GST-SIRT2-ΔCT, or GST alone for control with commercially available purified 
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tubulin in the presence of NAD+. In time course experiments we observed that 
SIRT2-ΔCT was more efficient in deacetylating tubulin at K40 compared to the wild-
type protein (Figure 5.4). This finding is consistent with the postulated activity of the 
CT in partially occupying the NAD+ binding pocket. 
 
Table 5.2: Hydrogen bond and salt bridge interactions between the CC and the 
CT in full-length SIRT2.  
 
Interaction ID Residue a  Residue b Distance (nm) c 
h1 A321 K173 0.30 (0.03) 
h2 N325 K99 0.29 (0.03) 
h3 N325 Q105 0.30 (0.02) 
h4 N325 E100 0.36 (0.09) 
h5 P326 K99 0.29 (0.02) 
h6 S331 D68 0.38 (0.10) 
h7 S331 E71 0.44 (0.19) 
h8 A339 D58 0.30 (0.02) 
h9 D341 S61 0.31 (0.03) 
h10 D341 S63 0.34 (0.07) 
h11 T345 R60 0.36 (0.10) 
h12 Q352 Q230 0.33 (0.08) 
s1 K333 D68 0.35 (0.11) 
s2 E349 R60 0.39 (0.19) 
s3 K350 E251 0.45 (0.14) 
a Residues belong to the CT. 
b Residues belong to the CC. 
c Atomic distances (h1-h12) between donor and acceptor, and center-of-mass distances (s1-
s3) between negative and  positive side chains, calculated on the equilibration trajectory from 
MD simulations of SIRT2. The standard deviations (SD) are also reported. 
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Figure 5.4: Tubulin deacetylation assay with SIRT2. (A) GST-SIRT2 wild-type 
(wt) or a C-terminally truncated GST-SIRT2-ΔCT fusion protein were incubated with 
commercially available purified tubulin in the presence of NAD+ for the indicated 
periods of time (0 to 90 minutes). GST was included as a negative control. The 
samples were subjected to SDS-PAGE and either stained by Coomassie blue (CB) or 
tubulin and acetylated tubulin were measured by Western blot analysis using specific 
antibodies (IB). (B) Quantification of three independent experiments. Mean values 
and standard deviations are indicated. Significant differences are indicated by an 
asterisk (two-sided students T-test). This assay was performed by Dr. Franziska Flick.  
 
An autoinhibitory role of CT domains has also been observed in vitro for other 
sirtuins, i.e. SIRT3 [266] (a member of the same sub-class9) and Hst2 (a protein 
homolog to SIRT210) [239]. In the latter the CT (which is much longer, i.e. 62 amino 
acids instead of 33 in SIRT2, see Figure 5.1A) completely occludes the active site 
[239] (see Figure 5.5). Our models, hence suggest that modifications of the CT (e.g. 
by phosphorylation and acetylation) might affect sirtuin deacetylase activities by 
changing the location and folding of CTH and thus regulating the loading and 
                                                
9Based on domain sequence homology, the human sirtuin proteins can be distinguished into 
four sub-classes: (i) sub-class Ia, SIRT1; (ii) sub-class Ib, SIRT2 and SIRT3; (iii) sub-class II, 
SIRT4; (iv) sub-class III, SIRT5; and sub-class IV, SIRT6 and SIRT7[105]. 
10The sequence identity between the two proteins is 42%. 
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positioning of NAD+ in the active center. Therefore we suggest that alterations in the 
flexibility of the CT or part of the CT due to post-translational modifications may 
modify its autoinhibitory activity by either enhancing or diminishing the interaction of 
the CT with the NAD+ binding pocket. In turn this might then affect the binding or the 
positioning of the NAD+, which are important determinants of catalytic activity. 
Consistent with this suggestion, the deacetylation activity decreases upon 
phosphorylation of SIRT2 at S331, which is located in the CT, both in vitro and in 
cells [44].  
 
 
Figure 5.5: Superposition of the most representative configurations of SIRT2 
(green) with the crystal structure of yeast Hst2 [239] (gray). The CT regions of 
SIRT2 and Hst2 are colored in red and salmon, respectively. 
 
SIRT2-pS331. To further validate the hypothesis that phosphorylation of the CT 
might interfere with SIRT2 function, we predicted the model of SIRT2 in the 
presence of phosphorylation at S331 (SIRT2-pS331). The good sampling and 
convergence of the 500 ns-long MD simulations on SIRT2-pS331 were confirmed by 
the PC analysis, i.e. the cosine contents for the first three PCs are 0.320, 0.231, and 
0.369. While the CC domain does not change significantly (backbone RMSD values 
are 0.24±0.02 nm with respect to the X-ray structure [52]), the CT shows large 
conformational changes (Figure 5.6, its average backbone RMSD during the 
simulations is 0.49±0.07 nm). Due to the repulsion between pS331 and E71 and D68 
in the cofactor binding loop, the backbone of the phosphorylated CT moves ~1.07 nm 
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away from the CC. pS331 forms a salt bridge with K333, and D68 salt bridges with 
K334. As a result, the CTH becomes fully unfolded and the autoinhibitory region 
moves deeper into the NAD+ binding pocket by ~0.15 nm compared to the 
unphosphorylated SIRT2 (Table 5.1). This new configuration of the CTH is stabilized 
by two salt bridges formed between R344 in the CT and D58 in the CC, and between 
R348 in the CT and D257 in the CC. T346 occupies the presumed binding site of 
nicotinamide ribose (Figure 5.6). The results of our simulations support the 
hypothesis that phosphorylation of the CT at amino acid S331 induces a 
conformational change that contributes to the regulation of the autoinhibitory region 
of the CT. These findings are consistent with the previous biochemical findings that 
phosphorylation of S331 inhibits SIRT2 catalytic activity [44]. In broader terms other 
modifications of the CT may also affect the interaction of the CT with the NAD+ 
binding site and thus regulate catalytic activity of SIRT2. 
 
 
Figure 5.6: Interaction of the S331 phosphorylated CT region with the NAD+ 
binding site. Superposition of the most representative configurations of SIRT2 (cyan) 
and SIRT2-pS331 (green). The CT of SIRT2-pS331 is colored in pink. The NAD+ 
cofactor in the SIRT2/NAD+ is represented by yellow sticks.  
5.3 Conclusions 
In summary, we present full-length molecular models of apo-SIRT2, the 
SIRT2/NAD+ complex and SIRT2-pS331 by using bioinformatics tools and MD 
simulations. Based on the models and the functional analysis of the CT and of the 
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phosphorylation at S331, we suggest that the C-terminal region of SIRT2 functions as 
an autoinhibitory region that regulates the deacetylation activity of SIRT2. This can 
occur by increasing the stability of the non-productive NAD+ in SIRT2/NAD+ and/or 
partially occupying the NAD+ binding site in apo-SIRT2. The inhibitory role of the 
CT region is consistent with the increased catalytic activity of a SIRT2 mutant that 
lacks this region. Phosphorylation at S331 causes large conformational changes in the 
CT that enhance the autoinhibitory activity of the CT region. This is consistent with 
our previous findings that CDK-dependent modification of S331 inhibits SIRT2 
catalytic activity both in vitro and in cells [44]. 
 
5.4 Methods 
Computational Chemistry. SIRT2 contains the CC domain (Figure 2.2B), for which 
structural information is available (PDB ID: 1J8F [52]) and two unstructured regions, 
the NT and the CT. CC includes a zinc ion, coordinated by four cysteine residues 
(C195, C200, C221 and C224) (see Figure 2.2B), but lacks the NAD+ cofactor [52], 
which is normally present in the CC of sirtuins [105,109,238,262,263]. CC shares the 
same domain architecture [52] and 26% sequence identity with Sir2-Af1 from A. 
fulgidus (PDB ID: 1ICI [109]). Hence, we have obtained an educated guess of the 
location of the NAD+ cofactor by superimposing the two structures. Next, we 
constructed structural models of the NT and CT regions by (i) homology modeling 
and (ii) ab initio modeling. (i) Being the BLAST webserver 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) not able to find suitable templates for neither 
region, we split the NT and CT into fragments, as described [267]. We identified 26 
templates (13 for NT and 13 for CT from the BLAST webserver, see Table A2) with 
sequence identities with the targets ranging from 48% to 100%. 200 models of the 
full-length SIRT2 isoform 2 were then generated using the MODELLER 9v9 package 
[252]. (ii) Ab initio modeling [268], using the Robetta webserver [269], resulted in 
five full-length SIRT2 models. 172 models out of 200 generated from homology 
modeling and all 5 models from ab initio modeling turned out to have 90% residues 
or more in the most favored regions of Ramachandran plots [270]. For this analysis, 
the Procheck program [271] was used. Six representatives, representing 86% of the 
200 homology models, were identified by a cluster analysis [272]. One ab initio 
model was selected among the five obtained. This shows the lowest difference (in 
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terms of secondary structure and root-mean-square deviations (RMSD)) compared 
with the SIRT2 CC crystal structure [52]. These seven selected full-length 
SIRT2/NAD+ models were inserted into a cuboid with edge lengths of 91 Å, 112 Å 
and 98 Å containing ~31,000 water molecules and six Na+ ions. The overall systems 
were neutral and underwent MD simulations using the GROMACS 4.5.5 code [273]. 
The all-atom AMBER ff99SB-ILDN force field [274-277] was used for the protein, 
Na+ and NAD+. The bonded plus electrostatic model and corresponding zinc AMBER 
force field (ZAFF) parameters (tetrahedral four cysteine zinc-bonding configuration, 
ref. [278]) were used for the zinc and its four cysteine ligands. The van der Waals 
parameters for the zinc ion were taken from AMBER ff99SB-ILDN force field [279]. 
The TIP3P force field [280] was used for the water molecules. All bond lengths were 
constrained by LINCS algorithm [281]. Periodic boundary conditions were applied. 
Electrostatic interactions were calculated using the Particle Mesh-Ewald (PME) 
method [282], and van der Waals and Coulomb interactions were truncated at 1.0 nm.  
 
SIRT2 has 7 histidines (H74, H90, H112, H150, H157, H165 and H312). We have 
determined their protonation states by combining visual inspection for predicting 
possible interactions (hydrogen bond patterns or salt bridges) and by using two 
servers (WHAT IF [283] and H++ [284]) evaluating the local effects of the flanking 
amino acids on histidines’ pKa. We have additionally run short MD simulations (10 ns 
for each protonation state) on one of the seven models to evaluate the effect of the 
different protonation states on the SIRT2 structure. We have chosen the configuration 
with the lowest RMSD (Table A3) in respect to the SIRT2 crystal structure for 
following productive MD simulations, i.e. H74 (Nε), H90 (Nε), H112 (Nδ), H150 
(Nε), H157 (Nε), H165 (Nε and Nδ) and H312 (Nδ)). The systems underwent 1,000 
steps of steepest-descent energy minimization with 1,000 kJ·mol−1·Å−2 harmonic 
position restraints on the protein, followed by 2,500 steps of steepest-descent and 
2,500 steps of conjugate-gradient minimization without restraints. The systems were 
then gradually heated from 0 K up to 302 K in 20 steps of 2 ns. After that, 
equilibration was performed. Finally, 150 ns-long productive MD simulations were 
carried out for each system in the NPT ensemble (constant temperature at 302 K, 
constant pressure at 1 bar and 2 fs time step by coupling the systems with a Nose-
Hoover thermostat [285,286] and an Andersen-Parrinello-Rahman barostat [287]). 
 48 
The most representative structure for each SIRT2/NAD+ model was identified by the 
cluster analysis [273] over the equilibrated trajectories, ranging from 30 ns to 120 ns.  
 
In order to screen across the seven full-length SIRT2/NAD+ models, each of them 
was docked onto one of SIRT2's known cellular partners [44], the cyclin A/CDK2 
complex [44] (see Chapter 4). Only one of the seven full-length SIRT2/NAD+ models 
could reproduce the conserved interaction patterns between cyclin A/CDK2 and its 
substrates as observed in a crystal structure [55] (Figure A7). This model was used 
also to predict the structure of the full-length SIRT2 model. The NAD+ cofactor was 
simply removed from the SIRT2/NAD+ model, and then 150 ns-long MD simulations 
were performed in a cuboid with edge lengths of 93 Å, 101 Å and 100 Å containing 
~30,000 water molecules and five Na+ ions. The most representative structure from 
the equilibrated trajectories (80-150 ns) was identified by the cluster analysis [273]. 
The most representative structure of SIRT2 was further used to predict the structure of 
the SIRT2-pS331 model. 500 ns-long MD simulations were performed in a cuboid 
with edge lengths of 85 Å, 106 Å and 95 Å containing ~25,000 water molecules and 
seven Na+ ions. The most representative structure from the equilibrated trajectories 
(200-500 ns) was identified by the cluster analysis [273]. Hydrogen bonds were 
defined to be present if the distance between the acceptor and donor atoms is below 
0.35 nm and the angle among the hydrogen-donor-acceptor atoms are below 30 
degree. 
 
Plasmids and recombinant proteins. Recombinant proteins were produced in E. coli 
BL21(DE)pLysS as GST fusion proteins using the constructs pGEX-SIRT2 (isoform 
2) and pGEX-SIRT2-∆CT (lacking the terminal 32 amino acids). Transformed 
bacteria were grown to an OD of 0.5 – 0.7 and protein expression was induced with 1 
mM IPTG at 21°C for 16 h. Bacterial pellets were lysed in buffer containing 20 mM 
Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 5 mM DTT, 1 mM Pefabloc SC, and 
14 µg/ml Aprotinin, sonicated, and centrifuged at 10.000xg at 4°C for 30 min. GST-
fusion proteins were separated from the cell lysate on glutathione-agarose (Sigma-
Aldrich). The column was washed in 100 mM Tris-HCl pH 8.0 and 120 mM NaCl, 
and eluted in 100 mM Tris-HCl, pH 8.0, 120 mM NaCl, and 20 mM Glutathione. The 
purified proteins were analyzed on SDS-PAGE and Coomassie Blue staining.  
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Deacetylation assays. For deacetylation assays 0.5 µg porcine tubulin (Cytoskeleton 
Inc.) was incubated in 50 mM Tris-HCl, pH 8.0, 10 % (v/v) Glycerol, 1 mM DTT, 0.1 
mM EDTA containing ProteoBlock protease inhibitor cocktail (Fermentas) with 1 µg 
of GST or GST fusion proteins. Tubulin (B-5-1-2, Abcam) and acetylated tubulin 
(K40ac antibody 6-11B-1, Sigma-Aldrich) were detected on Western Blots as 
described before [44]. 
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Chapter 6 Molecular simulation-based structural prediction of 
protein complexes in mass spectrometry: The human insulin dimer  
6.1 Introduction 
Proteomics, the large-scale characterization of proteins and their interactions, is key to 
understand cellular processes including signaling pathways, metabolism, and gene 
transcription [6,8,9]. Arguably, the most powerful tool for studying functional 
proteomics is protein electrospray ionization (ESI) mass spectrometry (MS) [9,23,56-
62]. ESI-MS detects rapidly and reliably proteins in complexes formed during cellular 
processes at physiologically relevant concentrations [140]. It provides the 
stoichiometry, topology, connectivity, dynamics and shape of multi-protein 
complexes when combined with ion mobility (IM)-MS experiments [8,142]. Using 
the IM-MS technique, collision cross sections (CCS) can be determined [8,9,142,144] 
with protein concentrations well below those required for high resolution (X-ray and 
NMR) as well as low resolution traditional structural biology techniques 
[9,24,58,147] such as electron microscopy [145] and tomography [146].  
 
ESI-MS has also been used for structural proteomics in combination with 
experimental structural biology techniques (e.g. X-ray and NMR) and/or 
computational techniques (e.g. homology modeling and protein-protein docking) 
[9,151,152,154-156]. These applications are based on the assumption that the 
vaporization of non-covalent protein complexes from aqueous solution into the gas 
phase (as occurs during ESI-MS) in general preserves the characteristic structural 
determinants of the complexes in water [63-67]. This assuption is consistent with the 
avaliable CCS data for some biomolecules and with the fact that intact non-covalent 
protein complexes in ESI-MS are indeed transferred into the gas phase [288-293]. 
However, direct proove for this concept has not been forthcoming at the atomistic 
structural level, because the structural determinants of gas phase protein complexes 
have remained largely unknown [67]. Thus, the preservation of these determinants on 
passing from solution to gas phase is still under debate for protein complexes. 
Predicting the structure of protein complexes under ESI-MS conditions, and in 
particular assessing whether native interactions in the gas phase reflect those in the 
aqueous phase, is therefore important for ESI-MS based structural proteomic studies.  
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A straightforward approach to improve the structural prediction is to run molecular 
dynamics (MD) simulations and select models that are consistent with the CCS 
[186,187]. However, these investigations have limited predictive power as no 
validations are provided against the main charge and the simulation is basically used 
as a tool to generate structural ensembles from which specific conformers can be 
selected [186]. More elaborate protocols have been developed for single proteins in 
the gas phase [63,68,188-190,193,194,197-199,204,209]. These approaches have 
predicted ensembles of structures consistent with the experimentally measured charge 
and CCS [68,190]. They have further suggested that desolvation leads to more 
compact overall protein structures while preserving the majority of the secondary and 
tertiary structures [63,68,188,189]. In addition, the fraction of hydrogen bonds 
(relative to the theoretical maximum) increases significantly upon passing from 
aqueous solution (on average 43%) to the gas phase (on average 56%) [193]. This 
suggests that proteins in the gas phase may be trapped in a low energy state, 
structurally close to the native state in water [194]. Our recent studies further indicate 
that the ionization state of a gas phase protein is the result of the balance between 
repulsive electrostatic terms and stabilizing forces that include salt bridges, hydrogen 
bonds, π-charge and long-range electrostatic interactions [68,188]. Therefore, these 
simulation schemes appear instrumental to predict the structural determinants of 
protein complexes. 
 
Recently, we have proposed an efficient approach to sample exhaustively the proteins' 
protonation state space, based on a hybrid Monte Carlo (MC)/MD scheme [68]. Here, 
we extend this computational scheme, originally developed for single protein ESI-MS 
structural predictions, to a protein complex, the human insulin dimer (hIns2 hereafter, 
Figure A8). hIns2 is present in vivo [294]. It is used for the treatment of diabetes and 
obesity [295,296]. Our predictions reproduce the experimental main charge state and 
CCS. They further show that, in the sub-ms time scale (possible times of the ESI-MS 
experiments to form stable gas-phase structures, ranging from ms to s [67]) the 
overall gas-phase structure of the complex rearranges already significantly. The final 
gas phase structure differs distinctively from the solution structure as large amplitude 
reorganizations take place in order to maximize intra- and intermolecular hydrogen 
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bond interactions, which are necessary for the formation of stable gas-phase 
structures. Hence, our current work provides evidence against the assumption that 
non-covalent complexes being transferred into the gas phase generally preserve their 
structural determinants in solution. 
6.2 Results and discussion  
Here (i) we first employed our hybrid MC/MD scheme-based protocol, used for single 
proteins [68], to explore the protonation state space of hIns2 and to identify the main 
charge state and its most probable conformer. Then, (ii) we performed sub-ms MD 
simulations on the latter in the gas phase to investigate its structural features. Both 
steps were validated by comparison with experiments. Comparison with independent 
MD simulations of the protein dimer, with different initial condition and/or force field 
was additionally made. 
 
(i) The protocol developed by us and used here for protonation state space exploration 
[68] was applied to hIns2 in the gas phase with different charge states ([hIns2]q, 
q=1+,2+,...,15+)  (see the Methods and Appendix A4). The protocol uses both MC 
and MD simulations and is based on standard force field energy augmented by 
additional energy terms associated with the gas-phase basicity (GB) of ionizable 
residues [68]. The initial structure of our calculations was taken from MD simulations 
of the protein complex in water at physiological pH, which was in turn based on a 
high resolution X-ray structure (see Figure A8 for further details). 
 
The GB corrected energies correlate with density functional theory (DFT) results 
much better than the energies derived from the original force field (Figure 6.1, see the 
Methods for further details). The corrected energies of the complex for fifteen charge 
states turned out to decrease largely already after few hundred steps (Figure 6.2A for 
the case of [hIns2]6+ and Appendix, Figure A9 and Figure A10). The identified lowest 
energy protonation states for each charge state are reported in Table A4.  
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Figure 6.1: Correlation plots of the differences in energy for 60 protonation 
states of the hIns2 relative to the lowest-energy protonation state. (A) Energy 
differences calculated with the OPLS/AA force field (∆EFF) [297] versus differences 
calculated with DFT (∆EQM) [68]. (B) Energy differences calculated with the 
OPLS/AA force field along with the GB correction (∆Ecorr) versus differences 
calculated with DFT (∆EQM). The correlation is much better with GB correction than 
with OPLS/AA (R2=0.81 and 0.03, respectively), confirming the crucial role of GB 
for estimating the energies of the protonation states. 
 
The protocol was validated by predicting the experimental main charge (which is 
usually the maximum charge for folded proteins [298]) of the complex under ESI. 
This is q=6+ [299]. We used the fact that the charge state of protein ions with the 
apparent gas-phase basicity (GBapp, see its definition in the Appendix A4.5) close to 
the GB of the solvent, from which the protein ions are formed, reproduces the 
experimental maximum charge states under ESI. The theoretical values are within 6% 
of the experimental values for 13 proteins [300]. Following published procedures 
[300,301], we estimated the maximum charge by calculating the intersection of the 
GBapp fitted line as a function of protein complex net charge with the line of the 
solvent GB. The intersection occurs at q=6+ (Figure 6.2B), matching the 
experimentally measured main charge for hIns2 generated from a solution at pH=7.4 
[299].  
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Figure 6.2: Protonation state space exploration. (A) GB corrected energy (Ecorr) as 
a function of MC step for the MC/MD sampling on hIns2 at the main charge state 
(q=6+). (B) Prediction of the main charge state of hIns2. GBapp values (in kJ/mol) 
were calculated for the lowest energy protonation states of hIns2 (black line and cycle 
symbols). Standard deviation from the average is given as error bars. When not 
visible, the standard deviation is smaller than the symbol size. The red horizontal line 
indicates the GB of water (660.3 kJ/mol taken from ref. [302]). The experimental 
main charge state [299] is shown by red solid diamond. 
 
(ii) 0.075 ms long MD simulations in the gas phase were performed on the lowest 
energy protonation state for the main charge state, i.e. [hIns2]6+. The simulations 
appeared to be gradually equilibrated already after ~55 µs as indicated by the 
convergence of the backbone heavy atoms root mean square deviations (RMSD) of 
the complex and other structural properties (e.g. radius of gyration (Rg) and center-of-
mass distance between monomers) as a function of simulated time (Figure A11A to 
Figure A11D). The convergence of the simulations has been probed by the cosine 
content of the first principal component (PC) according to the Hess method [261]. 
When the cosine content is close to 1, it means that the system is far from 
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convergence. The cosine contents of our systems turn out to be close to 0, indicating a 
good sampling of insulin dimer conformations (see Appendix A4.6 for details).  
 
Overall our simulations indicate that the β-strand secondary elements are more stable 
than the α-helices, i.e. the average contents of β-sheets in water and in the gas phase 
are 4.0±1.2% and 3.9±1.1%, respectively, while the ones of α-helices are 38.7±3.0% 
and 2.8±4.0%, respectively. These findings are consistent with the lower stability of 
α-helices than β-sheets in the gas phase observed from previous simulations 
[303,304]. Specifically, the two-stranded antiparallel β-sheet motif at the interface of 
the two insulin monomers was well maintained during MD simulations (Figure 6.3A 
and Figure 6.3B). This motif was stabilized by monomer-monomer hydrogen bonds in 
solution (Figure A8E), such as in [305,306]. In contrast, the six α-helices, stabilized 
by hydrophobic interactions in solution (Figure A8F), unfolded after ~25 µs (Figure 
6.3A and Figure 6.3B).  
 
Our MD simulations of the protein complex in solution suggest that 230.2±8.6 
hydrogen bonds are formed between the protein complex and the solvent. A 
significant fraction of these (~12%) is replaced by hydrogen bonds within the protein 
complex on passing from solution into the gas phase. Hence, several of the protein 
hydrogen bonds functionalities, forming hydrogen bonds with the solvent, rearrange 
in the gas phase so as to form intra- and intermolecular hydrogen bonds not present in 
solution. Figure 6.4 shows the reorganization of one of the hydrogen bond networks 
between solution and gas phase (panel A and B, respectively). In contrast, the 
intermolecular van der Waals contacts did not reveal significant changes (Table A5). 
This may be due, at least in part, to the fact that these contacts are maximized both in 
solution (because of the hydrophobic effect [307]) and in the gas phase. 
 
The Rg of the complex in the gas phase (1.30±0.01 nm) decreased compared to the 
one in water (1.37±0.01 nm, see Figure A11A and Table A5). This is consistent with 
previous simulations both on single proteins and protein complexes [68,186,188]. 
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Figure 6.3: MD simulations in the gas phase of the [hIns2]6+. (A) Models of 
[hIns2]6+ obtained from MD simulations in the gas phase (from left to right, at 0 µs, 
5.7 µs, 8.1 µs, 27.6 µs, 36.3 µs, 42.6 µs, 54.9 µs, and 75.0 µs). The monomer I and II 
are indicated in cyan (lower structure) and green (upper structure), respectively. The 
α-helices and β-sheets are highlighted in blue and red, respectively. Schematic 
representations of the complex models are shown below the complex structures, at 
corresponding positions on the simulation time axis. The backbone RMSD values of 
the models in respect to the one at 0 µs are 0.25 nm (5.7 µs), 0.54 nm (8.1 µs), 0.55 
nm (27.6 µs), 0.49 nm (36.3 µs), 0.45 nm (42.6 µs), and 0.49 nm (54.9 µs), and 0.50 
(75.0 µs). (B) Secondary structure analysis for [hIns2]6+. (C) The angle between the 
center of mass (COM) of monomer I – β-sheet region – monomer II. (D) CCS values. 
The experimental value of 12.9 nm2, as reported [299], at the main charge state is 
indicated by a red solid line and its 5% variations are indicated by the dashed lines. 
(E) Number of contact pairs between the carbon atoms of the monomers within 0.60 
nm. 
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During the simulations we also observed progressive rearrangements of the two 
insulin monomers with respect to each other. Specifically one of the two monomers 
(monomer I (cyan) in Figure 6.3A) first rotated by about 30 degrees relative to the 
other after 6 µs (Figure 6.3C), with additional small rearrangements when the helices 
unfolded (Figure 6.3B), and then stepwise rotated backward by about 20 degrees 
between 28 µs and 55 µs. The angle values between monomer I – β-sheet – monomer 
II at the end of the MD simulation were similar (~1.5 degree of difference) to the 
initial values.  
 
Accordingly, the evolution in time of the number of hydrogen bonds within the whole 
complex and those between monomers decreased (from 90.3±4.6 to 80.6±4.7 and 
from 14.6±1.6 to 13.4±1.5, respectively) after 6 µs and stepwise increased (from 
80.6±4.7 to 92.8±4.6 and from 13.4±1.5 to 15.3±1.5, respectively) from 28 µs to 55 
µs (Figure A11E and Figure A11F). At the end of the simulation, these numbers were 
larger than those of the complex in water (Table A5). Stepwise rearrangements to 
maximize inter- and intra-molecular hydrogen bonds in the formation of gas phase 
structures has also been observed in monomeric proteins [308]. In contrast, the 
number of van der Waals contacts first increased and then decreased, then increased 
again and finally were maintained in the latter part (after 55 µs) of the simulations 
(Figure 6.3E). At the end of the simulation the number was comparable to the starting 
situation, as we discussed above. 
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Figure 6.4: Comparison of a local inter- and intra-molecular hydrogen bond 
network in water (A) and in the gas phase (B). The final snapshots obtained from 
the MD simulations in water and in the gas phase at the main charge were selected. 
The monomer I and II are indicated in cyan and green, respectively. The water 
oxygen atoms are indicated by yellow balls. Nitrogen, dark blue; oxygen, red, 
hydrogen, white. Hydrogen bonds are shown as dashed lines. 
 
Next, we investigated the largest scale motions of the system by essential dynamics 
analysis (EDA) [309] (see Methods). In the combined water-and-gas-phase 
trajectories (see Methods for details), the largest scale motion involves a fast 
compaction of the complex and an unfolding/refolding transition of the α-helices 
(Figure A12A). Instead in the converged part of trajectory of the gas phase (i.e. the 
latter 0.020 ms, see discussion above and Figure 6.3) the largest scale motion entails a 
twisting of each subunit relatively to the other (Figure A12B). This suggests that after 
the system achieves equilibration in the gas phase, the compaction motion is less 
relevant than in solution, possibly because of the observed structural changes on 
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passing from water into the gas phase. Notably, the largest scale motion calculated for 
the entire simulation in the gas phase is similar to that of the combined water-and-gas-
phase trajectories  (Figure A12C). Thus, the initial, non-equilibrated gas phase motion 
retains a “memory” of the simulation in solution.  
 
Importantly, the calculated CCS values obtained from the gas phase simulations 
(12.8±0.2 nm2), reproduced the experimentally determined value (12.9 nm2) [299]. 
However, we found that the calculated CCS values were not sensitive enough to 
detect the subtle, yet significant structural arrangements described above (Figure 6.3 
and Table A6). Indeed, the calculated CCS shows no correlation with other gas-phase 
structural properties (Figure A13). As a further test to prove this issue we also 
calculated the CCS (Table A6) before (e.g. at time 5.7 µs) and after (e.g. at time 8.1 
µs) the turn of monomer I.  The CCS variation is about 0.1 nm2 (from 12.6 nm2 to 
12.7 nm2), a value within one standard deviation from the average values. 
 
Finally, to check the dependence of conformational dynamics of the complex on the 
microscopic initial conditions and on the force field, we performed additional MD 
simulations (see Table A5 and Figures A14, A15 and A16) on the lowest energy 
protonation state for the main charge state (q=6+) in the gas phase. Specifically, we 
performed (1) two additional 0.035 ms long OPLS/AA-based [297] vacuum 
independent simulations with different starting velocities and (2) one additional 0.025 
ms long vacuum simulation with the GROMOS 43a1 force field [310]. Selected 
averaged structural properties calculated from these simulations are similar to each 
other (Table A5). The only exception is the slightly more compact structure obtained 
from the GROMOS 43a1-based simulation. This may be due, at least in part, to the 
overestimation of London forces in this force field [311]. Taken altogether, these 
results indicate that our calculations are basically independent of the initial 
microscopic conditions and the adopted force field. Despite the similarities of the 
observed average structural properties, several possible pathways and intermediate 
conformers exist upon transfer from water into the gas phase (Figures 6.3, A14, A15 
and A16), consistently with what has been observed previously [312-314]. 
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6.3 Conclusions 
We have reported a systematic exploration of the charge and conformational space of 
the hIns2 non-covalent complex in the gas phase by using a hybrid MC/MD approach 
and sub-millisecond MD simulations. The long time required for observing structural 
changes such as the unfolding of the helices (~25 µs), as well as other conformational 
rearrangements, confirms that conformational changes in the gas phase may happen 
over long time scales (from µs to ms) [67,315,316]. Our calculations correctly 
reproduce the experimental main charge and the CCS measured in solution at pH=7.4 
[299]. Hence, molecular simulations approaches such as the one reported here may be 
a useful tool to (study and) complement the structural analysis of protein complexes 
via ESI-MS. We suggest that distinct protein complexes differ from one another when 
their structural properties are determined in gas phase or in solution. This is due to a 
substantial structural reorganization as a consequence of the maximization of intra- 
and intermolecular hydrogen bond interactions, which are necessary for the formation 
of stable vacuum structures. 
 
Therefore, care should be exerted when interpreting ESI/IM-MS data that are solely 
based on NMR and/or X-ray structural information. Consistent with this, recent 
experimental work also illustrates that the comparison between measured and 
calculated CCS based on X-ray structures can only provide a semi-quantitative 
estimate [317-320]. This may be attributed to the considerable uncertainties (from 0 to 
~40%) involved in the experimental measurements of CCS related to drag 
enhancement of protein ions in the drift tube and other factors [317-319], as well as to 
the compaction of protein structure in the gas phase in comparison to the 
corresponding X-ray crystal structure [319].  
6.4 Methods 
We first performed MD simulations in water based on the X-ray structure of hIns2 
(1.0 Å) (PDB ID: 1MSO [321]). The protonation states of residues in solution were 
assigned according to the corresponding pKa values calculated by using the H++ 
webserver [284]. As a result, H26, H31, R43, K50 and N-terminal residues (G1, F22, 
G52 and F73) were positively charged and E4, E17, E34, E42 and C-terminal residues 
(N21, T51, N72 and T102) were negatively charged. The total charge of the complex 
is 0. hIns2 was inserted into a water box with edges of 71×52×63 Å3 (in total 22,519 
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atoms). The AMBER ff99SB-ILDN force field [274-277] and TIP3P force field [280] 
were used for the protein complex and for water, respectively. Periodic boundary 
conditions were applied. Electrostatic interactions were calculated using the Particle 
Mesh Ewald (PME) method [282], and the cutoff for the real part of the PME and for 
the van der Waals interactions was set to 0.9 nm. All bond lengths were constrained 
using the LINCS algorithm [281]. Constant temperature and pressure conditions were 
achieved by coupling the systems with a Nosé-Hoover thermostat [285,286] and an 
Andersen-Parrinello-Rahman barostat [287]. One time-step of 2 fs was employed. 
The protein complex underwent 1000 steps of steepest-descent energy minimization 
with 1000 kJ·mol−1·Å−2 harmonic position restraints on the protein complex, followed 
by 2500 steps of steepest-descent and 2500 steps of conjugate-gradient minimization 
without restraints. The system was then gradually heated from 0 K up to 300 K in 20 
steps of 2 ns. 100 ns long MD simulation at 300 K and 1 atm pressure was carried out 
using GROMACS 4.5.5 [273]. The structure nearest to the average conformation of 
the complex in aqueous MD simulation (see Figure A8) was employed as starting 
structure for the MC/MD exploration of the protonation state space. The solvent 
molecules were removed.  
 
The MC/MD simulations (see Appendix A4.3 and Chapter 3 for details) were based 
on the OPLS/AA [297] force field energies augmented by additional energy terms 
associated with the GB of ionizable residues [68]. To validate the augmented term, 
the energies of 60 selected protonation states for q=6+ without and with the GB 
correction, as well as with DFT were calculated using the Becke exchange and Lee-
Yang-Parr correlation functional (BLYP) [322,323] and the TZV2P Gaussian basis 
set [324]. As in ref. [68,188,325], only the N-terminal and C-terminal residues and, R, 
K, H, Q, D, and E residues were allowed to protonate or deprotonate. We chose the 
OPLS/AA [297] force field because it offers the most complete set of base/conjugate 
acid pairs for these residues, e.g. the force field parameters for the deprotonated 
arginine residue are missing in AMBER [326] or CHARMM [327] force fields. Issues 
related to a particular choice of the force field have been carefully addressed in our 
earlier work [68,188]. Specially, we showed that three different force fields 
(GROMOS 41a1 [310], AMBER99 [326], and OPLS/AA [297]) give the same gas-
phase charge state for nine proteins of different size and fold, when the calculations 
were limited to protonation states containing the ionized residues common to all of 
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the three force fields [68]. We considered protonation states at total charge states from 
q=1+ to q=15+ (this includes the experimentally measured q=6+ [299]). The MC/MD 
protocol converged after a number of MC steps in the range of 1,500 to 6,500, 
depending on the charge state (over a total of ~4,000 to ~120,000,000 possible 
protonation states for each charge, see Table A7) were performed for various charge 
states.  
 
The lowest energy protonation state for the main charge state (q=6+) underwent MD 
simulations at 300 K for 0.075 ms in the gas phase with the same setup as the one 
described for the aqueous MD simulation, except that the time steps were 1.5 fs and 
the force fields was OPLS/AA [297]. To check for dependence on the microscopic 
initial conditions, additional two MD simulations, each 0.035 ms long, on the same 
protonation state were performed using different starting velocities. To check for the 
dependence of the results from the force field, we also performed 0.025 ms long MD 
simulation using GROMOS 43a1 [310]. The latter force field along with OPLS/AA 
[297], unlike others such as AMBER [326] and CHARMM [327], have standard 
parameters for deprotonated arginine residues. The latter are present in the identified 
lowest energy protonation state of [hIns2]6+ (see Table A4). Furthermore, MD 
simulations on other lower energy protonation states at the main charge state, with 
charges located on different residues, have been also carried out (see Table A9 and 
Appendix 4.6).  
 
Secondary structure elements were detected by using Define Secondary Structure of 
Proteins (DSSP) [328]. All figures for the visualization of structures were drawn 
using PyMOL (Molecular Graphics System, Version 1.3, Schrödinger LLC). CCS 
values were calculated for structures every 73.5 ns using the trajectory method [329] 
implemented in the MOBCAL code [184]. The EDA [309] was carried out for the 
whole (0.010 µs long) trajectory in water combined with the whole (0.075 ms long) 
trajectory in the gas phase, for the whole gas-phase one alone and for the converged 
part (0.055 to 0.075 ms) of the trajectory in the gas phase. The EDA was performed 
after iterative superposition of the MD trajectories on the crystal structure of hIns2. 
The ProDy (Protein Dynamics & Sequence Analysis) interface [330] implemented in 
VMD1.9.1 [331] was used for the visualization of EDA. The MC calculations were 
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carried out using standard Metropolis sampling [332] written as a bash/awk shell 
script, the MD using GROMACS 4.5.5 [273]. 
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Chapter 7 Conclusions 
Determining the structural facets of the human interactome is key for pharmacological 
research. It may lead to development of better diagnostics and to the identification of 
new therapeutic targets [20-24]. Biocomputing is successfully providing great 
advances in structural proteomics [333]. Here, armed with an arsenal of structural 
bioinformatics and molecular simulation approaches, I have investigated two systems 
of interest in the lab of Prof. Lüscher. 
 
First, I have focused on complexes between cyclin-dependent kinase 2 (CDK2), 
important for cell proliferation [31,32], and some of its cellular partners [55,82,83],  
namely sirtuin 2 (SIRT2) and p27KIP1.  
SIRT2 is a novel potential target to treat cancer and age-related diseases. SIRT2 is a 
nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase, which controls 
cell cycle progression [46-51]. Overexpression of SIRT2 contributes to tumor 
progression [334], while its inhibition has a neuroprotective role against the toxicity 
of α-synuclein in Parkinson’s disease [48]. Unfortunately, the structural facets of the 
protein are lacking. Hence, here by using bioinformatics tools and molecular 
dynamics (MD) simulations, I have provided the full-length models of the protein 
first, without and with the NAD+ cofactor (SIRT2 and SIRT2/NAD+), as well as with 
a phosphorylated S331 without NAD+. My in silico models, combined with in vitro 
approaches from Prof. Lüscher’s Lab, provide a consistent picture based on which the 
C-terminal residue functions as an autoinhibitory region to regulate the activity of 
SIRT2 through partially occluding the NAD+ binding site in SIRT2 and/or stabilizing 
the NAD+ in a non-productive state in SIRT2/NAD+. This occlusion is increased by 
phosphorylation at S331. These insights provided by my work might help to design 
specific inhibitors to control SIRT2 deacetylation activity for therapeutic applications. 
p27KIP1 regulates cell proliferation through interactions with CDKs and cyclins, which 
plays a role as tumor suppressor [53]. Phosphorylation at T187 by CDKs acts as a 
signal for the degradation of p27KIP1, which tightly controls the protein level [53]. I 
have modeled the p27KIP1 C-terminal peptide containing T187 by bioinformatics 
tools. 
Next, I have performed docking calculations between CDK2 and these two in vivo 
cellular partners, SIRT2 and p27KIP1. The calculations suggest that these substrates 
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display a similar mode of binding to CDK2 as the model peptide resolved in a crystal 
structure [55]. The identified structural determinants of such interactions can be 
fruitfully used as templates for drug design approaches.  
 
Finally, I have focused on the structural prediction of protein complexes in mass 
spectrometry (MS). Protein electrospray ionization (ESI) MS-based techniques are 
widely used to provide insight into structural proteomics [9,23,56-62]. Their 
applications are based on the assumption that the vaporization of non-covalent protein 
complexes from aqueous solution into the gas phase (as occurs during ESI-MS) in 
general preserves the characteristic structural determinants of the complexes in water 
[63-67]. Here I have investigated the applicability of this assumption by extending a 
structural prediction protocol for single proteins in ESI-MS from our group [68] to 
protein complexes. I have applied the protocol to the human insulin dimer (hIns2) as a 
test case, validating my calculations by reproducing the experimental main charge and 
the collision cross section measured in solution at pH=7.4 [299]. The important 
outcome of my simulations is that distinct protein complexes differ from one another 
when their structural properties are determined in gas phase or in solution. This is due 
to a substantial structural reorganization as a consequence of the maximization of 
intra- and intermolecular hydrogen bond interactions. Therefore, care should be 
exerted when interpreting ESI-MS data that are solely based on NMR and/or X-ray 
structural information.  
 
In conclusion, in this thesis, I have investigated by computational methods a variety 
of pharmacologically relevant proteins and protein complexes, which may represent 
novel targets for therapeutic strategies against cancer and neurodegenerative diseases. 
Moreover I have validated the applicability of ESI-MS, one of the most widely used 
experimental techniques in proteomics for protein-protein interaction studies.  
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Chapter 8 Methods 
Knowledge of 3D structures and dynamics of proteins is pivotal to elucidate almost 
all biological phenomena. It is also beneficial to the design of drug molecules and 
proteins. Experimental techniques, such as X-ray and NMR, have advanced and there 
are around 90,000 (http://www.rcsb.org/pdb/statistics) experimentally determined 
high-resolution 3D structures in the Protein Data Bank (PDB) [335], but there are far 
more known protein sequences with more than 69,000,000 sequences 
(http://www.uniprot.org/statistics) listed in the Universal Protein Knowledgebase 
(UniProtKB) [336]. Therefore, the gap between known protein sequences and solved 
structures by experiments is immense. Moreover, no experimental technique currently 
allows accessing all the biological relevant time scales of protein motions with high 
resolution [337,338]. Biomolecular modeling offers the potential of bridging the gap 
between structure and sequence, as well as providing invaluable high-resolution 
information about protein motions with various time scales [338]. Broadly, two main 
computational approaches exist to predict structural determinants and extract 
functional insights of proteins: structural bioinformatics and physics-based 
simulations.  
 
Structural bioinformatic methods use the statistical analysis of protein sequences and 
structures to understand their function and to predict 3D structures, such as sequence 
alignment, homology modeling, ab initio (de novo) modeling and docking. Physics-
based simulations use the principles from physics and physical chemistry to study the 
function and folding of proteins, which encompass molecular dynamics (MD), Monte 
Carlo (MC), quantum mechanics and many established procedures and methods 
[337]. Since both classes of approaches have been extensively used in this thesis, their 
fundamental principles are outlined in this chapter. 
8.1 Structural bioinformatics 
8.1.1 Sequence alignment 
Sequence alignment aims to match homologous characters that are descended from a 
common ancestor [339]. It can be applied to both gene (nucleotides) and protein 
sequences (amino acids). The latter application may help to infer the evolutionary 
relation, the post-translational modification sites, or the function of proteins.  
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The variation of protein sequences during evolution may affect or not the protein 
functionality. The mutation probability of each amino acid into another depends on 
their physicochemical similarity. Thus, the alignments can be ranked by assigning a 
substitution score [340,341]. Evolutionary events such as insertions and deletions in 
the sequence represent one of the major sources of change at the molecular level 
[342]. These gaps are, however, less frequent events than mutations. They are taken 
into account in sequence alignment algorithms through the application of gap 
penalties [343].  
 
Accordingly, the use of alignment-based pairwise sequence comparison emerges 
[344]. It is routinely used to detect protein homologs that diverged more than 2 billion 
years ago [345]. Pairwise sequence alignment [346] consists of maximizing a 
similarity measure between two sequences. The procedure can be extended to any 
number of sequences, thereby defining an N-dimensional matrix, where N is the 
number of sequences in the query [347]. The two main classes of pairwise alignments 
are: (i) global alignments, which try to maintain a correspondence over the entire 
length of the two proteins; and (ii) local alignments, where only the most similar parts 
of the proteins are aligned. Hybrid methods, known as semiglobal or glocal (global-
local) methods, attempt to find the best possible alignment by creating a map that 
transforms one sequence into the other while allowing for rearrangement events 
[348]. 
 
Multiple alignments are more informative than pairwise alignments, since their results 
can be related to various protein structural features, but turn out to be much more 
computational expensive than pairwise alignments [349]. After the advent of large 
genome projects and the consequent explosion of sequence data in public databases, 
the role of multiple sequence alignments has proved to be very important not only for 
the identification of conserved motifs or key functional residues in a family of 
proteins and in phylogenetic inference studies to define the evolutionary relationships 
between organisms [350], but also to perform comparative analysis at the genome 
level. This approach, instead of simply transferring annotation from one sequence to 
another, analyses protein families and their evolution, as well as it detects remote 
homologs [351]. This information confers improved accuracy to most of the 
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computational methods used in proteomics, from gene identification and validation to 
the determination of the protein 3D structure and the characterization of its molecular 
and cellular functions [352]. 
 
However, while the optimal solution to a pairwise alignment can be found within 
reasonable time, multiple sequence alignments are significantly more computationally 
demanding. First of all, it is not straightforward to select the best scoring function 
according to the phylogeny of the sequences. Hence, they are often assumed to be 
unrelated. Second, the computational cost of the possible use of dynamic 
programming grows exponentially with the number of sequences. A commonly used 
approach is therefore to do progressive alignment [353], where multiple alignments 
are built through the successive construction of pairwise alignments. This permits to 
study a higher number of distantly related sequences. Progressive methods are very 
dependent on the initial alignment, and errors made at any stage of the multiple 
alignment are propagated through to the final result. Thus, they are more likely to 
perform well for closely related sequences, which may be seen as a limitation of such 
methods. On the other hand, progressive methods provide a good compromise 
between time spent and quality of the resulting alignment, being efficient enough to 
deal with more than 1000 sequences [350]. In addition, many progressive methods, 
developed in the last 15 years, are able to correct the biased selection of the sequences 
by adding scaling factors weighted on the phylogenetic distance to their scoring 
function [354,355] or by including biological information, as in DIALIGN [356] and 
ClustalW [357]. The latter is the most widely used algorithm for multiple sequence 
alignments that has been used in this thesis. The alignment in ClustalW is achieved 
via three steps [358]:  
1. Pairwise alignment (calculating a distance matrix between each pair of 
sequences). 
2. Guide-tree generation (constructing a phylogenetic tree that represents the 
genetic differences among the sequences). 
3. Progressive alignment from the nearest to the farther sequences to obtain the 
multiple alignment. 
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8.1.2 Homology modeling 
Homology modeling, known also as comparative modeling, is a computational 
procedure for generating 3D models for proteins of unknown structure and known 
sequence, based on the major observation that during evolution, the structure of 
protein is more stable and changes much slower than the associated sequence; hence 
similar or even distantly related sequences adopt practically similar structures [359-
361]. Rost [362] has derived a precise limit for this rule based on an extensive 
analysis of resolved protein structures (Figure 8.1). For pairs of distantly related 
proteins (sequence identity ~20%), the regions with the same fold may comprise less 
than half of each molecule [363,364]. Hence, a "twilight zone" of 20-35% sequence 
identity was defined, in which it is not possible to unambiguously distinguish between 
protein pairs of similar and non-similar structure [362]. The quality of homology 
modeling in the "twilight zone" may therefore vary widely [365]. Models belonging 
to this zone may however be used to refine NMR structures, to find binding/active 
sites by 3D motif searching or to predict approximate biochemical function [360]. 
Generally, when the sequence identity exceeds 30%, “safe” (reliable) homology 
models can instead be constructed [366]. 
 
Homology modeling is commonly composed by four main steps in constructing 
models [360]:  
1. Template identification 
2. Target-template alignment and correction  
3. Model construction (backbone generation, loop modeling, side-chain 
modeling and model optimization)  
4. Model evaluation  
that have been described in the next subparagraphs (see also Figure 8.2).  
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Figure 8.1: Relation between sequence and structure homology. Two proteins 
share the same 3D-structure when their sequence identity falls in the safe homology 
zone (upper part of the picture). The figure is adapted from refs. [362,364]. 
 
8.1.2.1 Template identification 
The selection of the template is the initial step. The sequence of the protein with 
unknown structure is used as a query for searching proteins with known 3D structures 
in structural databases like the PDB [367,368]. A possible template in the safe 
percentage identity zone (Figure 8.1) can be identified with simple sequence 
alignment programs, such as BLAST [369] or FASTA [370]. These programs work 
by calculating a series of pairwise sequence alignments between the target sequence 
and each of the database sequences independently, and then providing a set of 
possible homologs ranked by the scores [371]. 
8.1.2.2 Target-template alignment  
Once the template is chosen, a pairwise sequence alignment is performed using 
specific and more sophisticated methods to arrive at a better alignment, because 
database search methods do not give an optimal alignment. A specialized alignment 
method often employed is the one implemented in the ClustalW program [357,372]. 
During the alignment, it is possible to include the sequence of the template and the 
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sequence to be modeled in a multiple sequence alignment with other homologs [357]. 
Conserved regions in a multiple sequence alignment of homologous sequences often 
refer to conserved structural regions, which can help to guide how the template 
sequence should be aligned to the target sequence. Also, because the template 
structure reveals which amino acids are located in the core of the protein (normally 
hydrophobic residues) or on the surface (normally hydrophilic residues), this 
information can also guide the alignment to correctly align physicochemically similar 
residues [357]. 
 
Figure 8.2: Steps in homology modeling. The figure is adapted from ref. [373]. 
 
8.1.2.3 Model construction  
Once an initial target-template alignment has been built, a variety of methods and 
programs, such as MODELLER [374], SWISS PDB Viewer [375], SCWRL [376] 
and web servers, such as 3D-JIGSAW [377] and SWISSMODEL [378], are available 
to build structural models of the proteins based on target template alignment. Model 
construction is composed by  
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• Backbone generation 
• Loop modeling 
• Side-chain modeling 
• Model optimization.  
For the proteins constructed in this work, the program MODELLER [374] was 
employed because it has been reported to generate homology models characterized by 
an improved stereochemical quality when compared with other automated programs 
[379]. 
 
The backbone generation in MODELLER is based on a technique known as 
“satisfaction of spatial restraints”, by which a set of geometrical criteria are used to 
create a probability density function for the location of each atom in the protein. The 
distance and dihedral angle spatial restraints are combined with stereochemical 
restraints on bond lengths, bond angles, dihedral angles and non-bonded contacts 
based on CHARM22 [327] force field. The probability density function restrains the 
Cα-Cα and backbone N-O distances, and backbone and side-chain dihedral angles for 
different residue types. The generated model violates these restraints as little as 
possible [380].  Insertions or deletions (gaps) in the alignment are placed out of 
helices and strands and within loops and turns, but these elements are difficult to 
predict; moreover, template and target may show quite different loop conformations 
[381].  
 
There are two main approaches for loop modeling: i) Energy based: one applies an 
energy function to sample and score random loop configurations; ii) knowledge 
based: one searches the PDB for known loops with endpoints that match the anchor 
residues between which the loop has to be inserted [371]. This is the approach 
exploited by MODELLER here. 
 
The side-chain modeling is performed for the fixed backbone atoms. The most 
successful approaches for side-chain modeling are knowledge based. They employ 
libraries of side-chain rotamers extracted from high-resolution X-ray structures [382-
385]. These libraries are backbone dependent, i.e. they store the distribution of the 
side-chain dihedral angles as a function of the backbone dihedrals. This not only 
 73 
increases the accuracy of the generated side chain, but also decreases the search 
space. Because certain backbone strongly favors certain rotamers [382]. 
 
Once all above steps are performed, model refinement (optimization) is required in 
order to increase the quality of the predicted model, because some minor details of the 
model may be wrong, such as the precise backbone conformation, hydrogen bond 
networks, etc. Model refinement is a tough task that requires an effective sampling 
strategy as well as an accurate energy function to guide the search through the 
conformational space. Homology model refinement is primarily focused on tuning 
alignment and modeling loops and side chains. Recent attempts have been made to 
increase alignment accuracy by using physical chemistry energy information and 
molecular simulations to refine the whole model [386-388]. 
8.1.2.4 Model evaluation 
The amount of errors in a homology model depends mainly on two factors:  
i) The sequence identity between target and template. If it is greater than 
90%, the target structure obtained can be compared to a 
crystallographically determined structure [363]; 
ii) The number of errors in the template. Experimentally determined protein 
structures are not perfect in some cases. There are countless sources of 
errors, ranging from poor electron density in the X-ray differaction map to 
simple human errors when prepare the PDB file for submission [389].  
For homology models that have the correct fold, a basic requirement is the 
stereochemical correctness. Some useful programs for evaluating stereochemistry are 
PROCHECK [390], PROCHECK-NMR [391], AQUA [391], SQUID [392], 
WHATCHECK [389]. The features of a model that are checked by these programs 
include bond length, bond angles, backbone dihedral angles, side chain torsion angles, 
the location of main chain conformation in acceptable regions of the Ramachandran 
map, the planarity of side chain rings and of peptide bonds, a proper environment for 
hydrophobic and hydrophilic residues, the absence of bad atom-atom contacts and of 
structural holes [393]. Based on these features, scoring functions such as the DOPE 
(discrete optimized protein energy) score [394], MolProbity clashscore [395], and the 
PROCHECK G-factors [391] can help distinguishing between homology models of 
higher and lower accuracy [396]. Other evaluation methods assess the environment of 
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each residue with respect to the expected environment as found in the known protein 
high-resolution X-ray structures. These methods are based on 3D profiles and 
statistical potentials of mean force [397] and are aimed at finding structures/folds 
compatible with a given sequence. Programs implementing this approach include 
Verify3D [398] and Anolea [399]. 
 
Ultimately, the predicted models can be validated by a variety of experimental 
techniques such as site-directed mutagenesis, circular dichroism, cross-linking mass 
spectrometry, fluorescence-based thermal shift, light scattering, molecular 
fluorescence resonance energy transfer (FRET) or electron microscopy. Conversely, 
such experimental data can be translated into constraints/restraints and introduced to 
guide the modeling in order to improve the accuracy of the models.  
 
8.1.3 Ab initio modeling 
When little or no experimental structural information about a protein or its homologs 
is available, the structure predictions have to be generated from scratch. This type of 
predictions has been termed as ‘ab initio’ or ‘de novo’ modeling [400]. Ab initio 
methods attempt to model structural features of proteins through knowledge-based 
and physics-based approaches. Evolutionary information is applied in generating 
sparse spatial restraints or identifying local structural segments.  
 
The idea for ab initio modeling is pioneered by Bowie and Eisenberg [401] who 
assembled new tertiary structures of proteins using small fragments (mainly 9 
residues long) cut from other protein structures. Based on this idea, Baker and 
coworkers developed ROSETTA [402], one of the most widely used ab initio 
modeling methods, which has worked extremely well for the Critical Assessment of 
Structure Prediction (CASP) targets [403]. In the ROSETTA method [402], the 
structures in a reduced knowledge-based model consisting of the heavy backbone 
atoms and Cβ atoms are first assembled from segments of nine residue in length with a 
simple nearest neighbor procedure to define the conformational space. Then, all-atom 
MC simulations with physics-based potential are performed to refine the low-
resolution models. Current ab initio predictions are mainly focused on small proteins, 
i.e. less than 150 residues. Several successful examples have been reported in 
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literature [404]. For example, using the ROSETTA program, Simon et al. reported 73 
successful structure predictions out of 172 target proteins with lengths of < 150 
residues, which RMSDs of Cα atoms are less than 7 Å in the top five models. Despite 
significant success of ab initio predictions [404], the computational cost of the 
procedure is still expensive (~150 CPU days for a small protein < 100 residues) for 
the routine predictions of larger proteins (typically >150 residues). The challenge for 
larger proteins is that a funnel-shaped energy landscape is more difficult to achieve 
using physics-based potential [405]. Therefore, ab initio modeling methods have been 
usually applied to large molecules in combination with homology modeling-based 
techniques, in order to improve the accuracy of models built from templates [406-
409].   
 
The determination of atomic structures of protein-protein complexes is laborious and 
not always successful using direct experimental methods [410]. As an alternative to 
experimental approaches, computational algorithms have been developed to predict 
the protein–protein complex structures. These computational approaches can be 
divided into two main classes: 
i) protein-protein (template-free) docking 
ii) template-based (or homology) docking. 
We introduced in the next two sections.  
8.1.4 Protein-protein docking 
From the structural point of view, modeling protein complexes is frequently achieved 
via docking [411]. The aim of docking is to find the best match for given 3D 
coordinates of separate protein moieties. Several docking algorithms have been 
developed throughout the years [412-416]. Docking strategies are composed of a fast 
search algorithm to obtain the candidate conformations and a high quality scoring 
function for the ranking of these conformations toward finding the near native model 
[411]. Most docking algorithms treat proteins as rigid bodies or permit side-chain 
motion only, in order to reduce the search in the conformational space [417]. But new 
promising approaches of flexible refinement, ensemble docking and explicit inclusion 
of flexibility during the entire docking process are constantly being developed [418]. 
 
The general scheme of docking can be divided into four major steps [412]: 
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1. Preprocessing stage: the proteins are analyzed to define their conformational 
space and interaction surfaces. This step simulates a conformational selection 
model, in which the conformational change in binding is thought to originate 
primarily from the conformational diversity of the unbound state [419]. The 
analysis of residues important for the protein-protein interaction can be 
supported by user-provided bioinformatics or experimental data. 
2. Rigid docking: a set of solutions is generated including at least one near-native 
structure. This implies the possible occurrence of steric clashes, because 
proteins in their unbound conformation can collide when placed in their native 
interacting position. 
3. Refinement: each candidate is optimized by small backbone and side-chain 
movements and by rigid-body adjustments. The resulting refined structures 
have better binding energy and hardly include steric clashes. This stage 
models an induced fit [420], a process where the initial interaction between a 
protein and a binding partner induces a conformational change in the protein 
through a stepwise process [421]. 
4. Scoring: the candidate solutions are scored and ranked according to different 
parameters such as force-field based potentials, agreement with known 
binding sites, deformation energy of the flexible proteins, buried surface area 
and desolvation energy terms. This stage is aimed to identify the near-native 
solutions among all the best-ranked candidates. 
 
The HADDOCK (High Ambiguity Driven protein-protein Docking) algorithm 
[422,423] was used in this thesis to predict protein complex models. Its docking 
protocol is slightly different from the one mentioned above and consists of three 
steps: 
 
1. Rigid-body energy minimization. In the initial randomization step, the two 
molecules, A and B, are separated by 25 Å and randomly rotated around their 
center of mass. Then they are allowed to rigidly rotate to minimize the 
intermolecular energy function. Two cycles of translational and rotational 
rigid body minimization are subsequently performed, and the two molecules 
are docked. The best structures in scoring term (typically 200 structures) will 
proceed to the second step. 
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2. Semi-flexible refinement in torsion angle space. This step consists of a semi-
flexible simulated annealing refinement in which the side chains and the 
backbone at the interface are allowed to move, in order to take into account 
some possible conformational rearrangements. This semi-flexible simulated 
annealing (SA) consists of several stages: a) high temperature rigid body 
search (2000 K, 500 steps); b) rigid body SA (cooling step from 2000 K to 
500 K, 500 steps); c) semi-flexible SA with flexible side-chains at the 
interface (from 1000 K to 50 K, 1500 steps); d) semi-flexible SA with fully 
flexible interface, i.e. including both backbone and side-chains (from 500 K to 
50 K, 1500 steps). The resulting structures undergo then steepest descent 
energy minimization. 
3. Final refinement in explicit solvent. The final step consists of a gentle MD 
simulation refinement in a 8 Å shell of TIP3P [280] water molecules of the 
remaining best structures (usually 200). During this stage, the system is first 
heated to 300 K, with flexible side-chains at the interface. 1500 MD steps are 
performed at 300 K, with a position restraint only on non-interface heavy 
atoms. Finally the system is cooled down (1000 steps at 300, 200, 100 K) 
imposing position restraints only to backbone atoms outside the interface. 
 
After each of these steps, structures are scored and ranked, and the best structures are 
retained for the next step [415]. Finally, the docking solutions are clustered based on 
pairwise backbone RMSD at the interface and sorted based on HADDOCK score 
[233]. Clusters are analyzed and ranked according to their average interaction 
energies (sum of electrostatic, van der Waals terms, desolvation energy, ambiguous 
interaction restraints (AIR) energy (see later)) and their average buried surface area. 
The first two interaction energies are evaluated by full electrostatic and van der Waals 
energy terms with a 8.5 Å distance cutoff using the OPLS [424] force field. 
 
To get accurate docking predictions, HADDOCK takes as input also bioinformatics 
information, biochemical and/or biophysical experimental data, like mutagenesis data 
or information about chemical shift perturbation upon binding. This information is 
used to define the distance restraints that can be used along the docking of two up to 
six biomolecules. 
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The AIR is a collection of restraints on two sets of residues, named active and passive 
residues, on the interacting surface. Active residues are for example those detected by 
experiments (mutagenesis, chemical shift perturbation upon complex formation) to 
make contact within the complex and solvent accessible. Passive residues are their 
closest solvent accessible neighbors that potentially make contacts. For every active 
residue, a single AIR restraint is defined between that residue and all active and 
passive residues on the partner biomolecule. An explicit AIR energy term is 
introduced into the calculation with the functional form of a harmonic potential 
(becoming linear after a given cutoff distance) that depends on an effective distance. 
The latter is calculated through the following formula: 
   
(8.1)  
where A and B are protein molecules, i iterates over all distance restraints, Natoms 
indicates all atoms of a given residue and Nres the sum of active and passive residues 
for a given protein. An upper limit to the effective distance (typically 2 Å) is enforced 
by HADDOCK [422]. If this limit is exceeded, the AIR energy becomes positive and 
the active residue experiences an attractive force towards the active and passive 
residues of the partner molecule. If not, the restraint is satisfied and the AIR energy 
and attractive force are zero for that restraint. Since many atom-atom distances 
inversely contribute to the effective distance, an AIR restraint is typically satisfied if a 
residue comes within 4-5 Å of any active or passive residue of the partner molecule 
[425]. It is also possible to randomly remove a fraction of the AIRs, if the definition 
of interacting residues is not clear. In this way, bad restraints could be discarded, 
allowing for better docking solutions. 
 
8.1.5 Template-based docking 
The physical principles of protein-protein binding and protein folding are the same, 
thus their modeling shares many aspects. Prediction of individual protein structures 
has evolved from the ‘first principles’ approaches to the currently dominating 
template-based (homology) modeling, largely because of the difficulty the template-
free methods face in delivering reliable solutions [220]. With the growth of the 
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experimentally determined structural data for protein complexes, template-based 
docking attracts increasing attention where a protein complex is modeled using 
sequence or structural similarity to a known protein complex (template) [220].  
 
In the template-based docking, the procedure is very elegant and straightforward: 
• Select a high quality non-redundant template dataset composed of known 
protein complexes. 
• Extrapolate the known data to threshold the targets by using the sequence or 
structural similarity. 
• Rank the predictions according to a scoring function, i.e. statistical potentials 
or energy functions [411].  
Construction of a non-redundant template set is the most challenging part for the 
template-based docking to model an interaction, because mistaken templates can 
produce false-positive binding regions. Hence, each template-based prediction 
method has different approaches to generate a sequence-homology or structural-
homology non-redundant template set.  
 
Apparently, template-based docking is computationally more efficient than the 
protein-protein docking strategies and easily applicable at the proteome scale 
[220,426,427]. However, the limitation of template-based docking is the availability 
of similar templates to the target proteins in the dataset, i.e. a complex structure 
cannot be predicted if there is no template similar to the targets forming the complex. 
For example, in this thesis besides HADDOCK, we additionally applied one of the 
most widely used template-based docking databases, Genome Wide Docking 
Database (GWIDD) [428], to predict the complex models between CDK2 and its 
substrates. However, due to lack of similar template for the substrates, no matching 
interaction was found in the database. 
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8.2 Physics-based simulations 
 
8.2.1 Introduction 
Physics-based molecular mechanics (MM) and quantum mechanics (QM) calculations 
are routinely used to investigate the structure, dynamics, thermodynamics and 
function of biological molecules. These classes of calculations have been employed 
for different aims along with different levels of detail and computational costs. From 
both structural and energetic points of view, QM is the best choice for any kinds of 
investigations. Unfortunately, the computational resources needed for even a small 
protein (less than 2000 atoms) at QM level have so far been prohibitive. As a 
compromise between computational cost and accuracy, MM-based simulations are 
much more commonly used for investigating biomacromolecules and their dynamics. 
 
8.2.2 Quantum mechanics calculations 
QM-based calculations use the laws of quantum physics governed by the Schrödinger 
equation to represent the matter. In particular, the full, time-dependent form of this 
equation describing the evolution of a set of N particles reads  
      (8.2) 
where Ψ is the wavefunction and H is the Hamiltonian operator associated to the 
system. If we assume the nuclei and electrons to be point masses and neglect 
relativistic interactions, the latter reads, for non spin-polarized systems: 
  (8.3) 
where α and β runs over the nuclei, while i and j over the electrons. e is the charge of 
electron and Zαe the charge of the nucleus α. riα is the distance between the nucleus α 
and the electron i, rij is the distance between the two electrons i and j, rαβ is the 
distance between the two nuclei α and β. The first two terms amount for the kinetic 
energy of the system while the third and fourth ones represent the interactions 
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between the nuclei, and between nuclei and electrons, respectively. The last term is 
the repulsive interaction energy between the electrons. 
 
Unfortunately, the Schrödinger equation cannot be solved exactly for molecular 
systems. Thus a variety of approximation methods have been developed in order to 
investigate the quantum properties of chemical compounds. 
 
QM explicitly provides the electronic distribution of the system. It can be used to 
investigate the chemical reactions, in which covalent bonds are formed and broken. 
Due to the high computational cost required to represent systems of just a few 
hundreds of atoms, QM approaches have so far found a limited application in the 
biological field [429]. In the past years a number of quantum methods for treating 
molecular systems were developed. In the subsequent sections a concise and non-
complete overview of the QM approaches used in the present work is given. 
8.2.2.1 Hartree-Fock self consistent field method 
The Born-Oppenheimer approximation is the assumption that the electronic and 
nuclear motion can be separated. The many-body wavefunction depends both on 
electronic and nuclear degrees of freedom, but since nuclei are by orders of 
magnitude heavier than the electrons, they move much slower. Thus the electrons are 
commonly able to relax very rapidly to the instantaneous ground-state potential given 
by the nuclear positions. For the electron evolution, the nuclei can therefore be 
considered as stationary points and their coordinates enter as parameters in the 
description of the electronic wavefunctions. In this approximation we can reduce the 
quantum problem to the electronic problem. The Hamiltonian operator for a N-
electron molecular system is 
   (8.4) 
The first sum contains the kinetic-energy operators for the N electrons. The second 
one contains the potential energy of the attractive interactions between the electrons 
and the nuclei where Ri is the distance between electrons and nuclei. The last sum is 
the term accounting for the interelectronic repulsion. Other relativistic terms are 
neglected because they are usually much smaller. 
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Due to the presence of the electron-electron repulsion term, the Schrödinger equation 
is not separable. The Hartree-Fock (HF) method approximates the Hamiltonian by 
neglecting the electronic repulsion terms. Hence, the wavefunction solution of that 
Schrödinger equation can be represented as a product of N hydrogen-like (one-
electron) orbitals. Thus variational methods that are not restricted to a particular 
molecular orbital can be used to investigate the total wavefunction. The procedure to 
estimate the terms of the variational function was developed by Hartree and is called 
HF self consistent field (SCF) method [430]. 
 
The procedure starts with an initial guess for the orbital coefficient of the N-hydrogen 
like function. These are usually linear combinations of Gaussian-type orbital (GTO). 
The starting value allows estimating the system energy and making a new guess to 
improve the real wave function approximation. The refinement procedure continues 
until both system energy and orbital coefficients reach a convergence.  
8.2.2.2 Møller-Plesset perturbation theory 
The most evident limitation of the HF SCF method is the lack of the electron-electron 
correlation, due to the most important approximation in the equation resolution. 
Correlation can be added as a perturbation from the HF wavefunction. This is the 
basic idea of the Møller-Plesset (MP) perturbation theory. In mapping the HF 
wavefunction onto a perturbation theory formulation, HF becomes a first-order 
perturbation. Thus, a minimal amount of correlation is added by calculating the 
second order MP2 term. Third-order (MP3) and fourth-order (MP4) calculations are 
also common. MP5 and higher calculations are seldom done due to the high 
computational cost (N10 time complexity or worse). 
 
MP methods, in contrast to the HF method, are not “variational”. In fact, it is possible 
to find MP2 solutions with a total energy smaller than the exact total energy. 
Depending on the nature of the chemical system, there seem to be two main patterns 
for the energy values in using successively higher orders of perturbation theory. For 
some systems, the energies of the approximate wave function solutions become 
successively lower and closer to the total energy in going from MP2 to MP3, to MP4, 
and so on. For other systems, the MP2 solution will have an energy lower than the 
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exact energy, MP3 higher, MP4 lower, and so on, with each correction providing a 
contribution that is smaller in magnitude but opposite in sign. 
8.2.2.3 Density function theory 
The density functional theory (DFT) approach to the solution of the quantum 
electronic problem is based on the Hohenberg-Kohn (HK) theorems [431]. These 
state that the energy of the ground state of a quantum system can be determined from 
its density (ρ(r)) instead of the wavefunction. Thus, a 3N dimensional problem in the 
wavefunction formulation (where N is the number of particles) becomes 3-
dimensional within the DFT framework: 
      (8.5) 
The HK theorems were reformulated by Kohn and Sham in 1965 [432] in a 
computationally accessible way. The principle is to map N interacting particles into N 
non-interacting particles with the same total density. The new formulation allows 
writing the density as summation of single-particle contributions: 
        (8.6) 
and the kinetic energy functional has an analytical expression: 
         (8.7) 
The total energy of the system is then expressed as: 
  (8.8) 
where Exc[ρ] is the so-called “exchange-correlation" functional and εi are the Kohn-
Sham (KS) orbital energies of the system with N non-interacting particles. These 
orbital energies are obtained by solving the KS equation: 
            (8.9) 
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where υeff is an effective potential in which the particles are moving. The KS 
equations are single-particle equations that exactly solves the many-body problem. 
However, the lack of an explicit analytical formulation of Exc[ρ] requires to 
approximate it. Different functionals were developed in the last years to this aim. In 
the present work we have used the Becke exchange [433] and Lee-Yang-Parr [434] 
correlation functional (BLYP). 
 
8.2.3 Molecular mechanics calculations  
MM models were adopted to investigate the large biomacromolecules due to the 
insurmountable difficulties to use the more accurate QM methods. With respect to the 
QM, MM makes further approximations to reduce the degrees of freedom of the 
investigated system. These approximations are based on the fact that most of the 
biological processes (e.g. protein folding, protein-ligand and protein-protein 
interactions) are driven by weak, non-bonded interatomic interactions, which can be 
very well described by classical potential-energy functions or “force fields” as part of 
a classical Hamiltonian of the biological system [435]. Some basic algorithms and 
techniques involved in MM are described and discussed in the following sections. 
8.2.3.1 Ergodic hypothesis 
In statistical mechanics, experimental observables of a system in thermodynamic 
equilibrium are described in terms of ensemble11 averages taken over a large number 
of microscopic states of the system. These states correspond to different 
configurations belonging to the same ensemble and satisfy the conditions of a 
particular thermodynamic state. An ensemble average is given by 
        (8.10) 
where A(pN,rN) is the observable of interest, and is expressed as a function of the 
momenta pN=(p1, p2, …, pN), and the positions rN=(r1, r2, …, rN) of the N particles, 
and ρ(pN,rN) is the probability distribution density of the states associated to a 
particular ensemble.  
Consider a canonical ensemble that describes a system in thermodynamical 
                                                
11An ensemble is a collection of different microscopic states of a system whose probability distribution 
defines the macroscopic properties of the system. 
  
A ensemble = dpNdrNA pN ,rN( )∫∫ ρ pN ,rN( )
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equilibrium at a given constant temperature (T) that can exchange its energy via very 
weak contacts with a thermal bath. It is generally the most useful ensemble in practice 
since we most often deal with systems in thermal equilibrium (constant T) with their 
surroundings. The probability density of the canonical ensemble is given by 
      (8.11) 
where H is the Hamiltonian of the system, kB is the Boltzmann’s constant and Z is the 
partition function 
      (8.12) 
where the integral is generally very difficult to calculate because all the possible 
microstates of the system must be considered.  
 
In MM-based simulations, in particular in MD simulations, the microstates of the 
specific ensemble are calculated sequentially in time, allowing to obtain the time 
average of the observable A:  
  (8.13) 
where τ is the simulation time, M is the number of frames in the simulation and 
A(pN,rN) is the instantaneous value of A.  
 
The “ergodic hypothesis” allows one to connect Eq. (8.10) with Eq. (8.13). In fact, a 
system is ergodic if, allowing it to evolve indefinitely in time, it will eventually pass 
through all its possible states. In this case the time averages becomes equal to the 
statistical ensemble averages: 
     (8.14) 
Therefore, under the assumption that the system is ergodic, MM-based simulations at 
the microscopic level could provide predictions and estimations (the time averages in 
Eq. (8.13)) of macroscopic properties measured from experiments (the statistical 
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averages in Eq. (8.10)). Really, the right side of Eq. (8.13) accurately approximates 
the ensemble average only if simulations sample sufficient amount of phase space. 
8.2.3.2 Potential-energy function and force field  
In MM models, the degrees of freedom of all electrons are neglected. Then, the 
characteristics of the system are only described as a function of the nuclear positions. 
The atom and chemical bond between two atoms are represented by a rigid sphere and 
by a harmonic oscillator obeying to Hook’s law, respectively. Harmonic oscillators 
are also used to represent the interactions between two atoms covalently bonded to a 
third one (angular terms) and between two planes identified by the first three and the 
last three atoms of a set of four atoms covalently bonded in a row (dihedral terms). 
The potential energy of a system is therefore generally described by terms 
representing covalent interactions between atoms, and noncovalent interactions 
between intra-/intermolecular atoms that are separated by more than two or three 
covalent bonds. The energy function further consists of a large number of 
parameterized terms that are chiefly obtained from experimental and/or QM studies of 
small molecules or fragments. They are assumed to be feasible for the larger 
biomolecules of interest. The set of functions along with the associated set of 
parameters is termed a force field [436]. A variety of force fields have been developed 
specifically for biomolecular simulations, such as AMBER [326], GROMOS [310], 
OPLS/AA [297], CHARMM [327], etc. The AMBER force field, for instance, 
consists of several discrete terms [326], each of which possesses a simple functional 
form describing an intermolecular or intramolecular force within the system: 
 
                                   (8.15) 
where kb, ka, and Vn are the bond length, bond angle and dihedral angle force 
constants, respectively. Likewise, li, θi, and ω are the bond length, bond angle and 
dihedral angle values in the current configuration, and the zero subscript represents 
the corresponding reference or equilibrium values (γ for dihedral angle). The first 
three terms in Eq. (8.15) represent the bonded interactions. The final two terms in the 
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function represent the London and Coulomb non-bonded interactions, respectively. εij 
relates to the well depth of London interaction, σij is the distance where the London 
interaction is zero, qi is the partial charge associated to atom i, ε0 is the effective 
dielectric constant, and rij is the distance between atoms i and j. 
 
Using Eq. (8.15), one may evaluate the potential energy of the system from the set of 
the atomic coordinates. Such simple form for the potential-energy function is good 
enough to allow dealing with systems composed of millions of atoms with the actual 
computational power [437]. However, the drawbacks of force fields must be taken 
into account. The force field-based approaches need the definition of all the chemical 
bonds a priori for each system under study. This is an insuperable limitation for any 
study involving chemical bond formation and/or breaking, like in enzymatic reactions 
and covalent drug-protein interactions. 
8.2.3.7 Molecular dynamics simulation 
MD simulations generate a sequence of microscopic states of the system in phase 
space as a function of time. MD simulations, in the most widely used versions, 
determine the trajectories of atoms and molecules by numerically solving the 
Newton's equations of motion for a system of N interacting particles 
       (8.16) 
where Fi is the force exerted on particle i, and mi  and ri are its mass and coordinate, 
respectively. The force acting on atom i can be expressed as the derivative of the 
potential energy U of the system with respect to its coordinate ri: 
      (8.17) 
Therefore, the Newton’s equations can be rewritten as: 
            (8.18) 
The potential energy of the system is defined by the force field employed, which in 
turn depends on the coordinates rN of all the particles of the system. Due to the 
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complexity of the system of equations, they are solved numerically using finite 
difference integration algorithms. Among the many possible methods to perform step-
by-step numerical integration of these equations, the favorable ones should take into 
account the following characteristics:  
a. There may be short and long timescales, and the algorithm must cope 
with both. 
b. Calculating the forces typically is the most computationally intensive 
part of the algorithm and should be performed as infrequently as 
possible. 
c. The trajectory of the particles’ coordinates should stay on the constant-
energy hyper-surface over long timescales (much longer than typical 
correlation times of the dynamical properties of interest), in order to 
sample the correct ensemble.  
Consistent with these features, the most common simulation algorithms are of low 
order, i.e. without involving high-order derivatives of positions, which are faster and 
allow larger time steps without jeopardizing energy conservation. In particular, the 
old Verlet algorithm [438], which requires only one evaluation of the forces at each 
time step, fulfills all these requirements and due to its simplicity is one of the most 
employed nowadays. The Verlet algorithm exists in various, essentially equivalent 
versions. The leapfrog [439] version of the Verlet algorithm, which was employed in 
this thesis, is described below. 
 
The leapfrog algorithm assumes that at time t positions ri, velocities vi and force Fi are 
known and it provides a recipe to get them at time t + Δt, where Δt is the time step.  
The algorithm is split in two phases. In the first one the velocity at a half time step is 
calculated by: 
vi t +
1
2 Δt
⎛
⎝⎜
⎞
⎠⎟ = vi t −
1
2 Δt
⎛
⎝⎜
⎞
⎠⎟ +
Δt
m Fi t( )       (8.19) 
and then the half time step position is obtained as: 
ri t +
1
2 Δt
⎛
⎝⎜
⎞
⎠⎟ = ri t( ) + Δtvi t +
1
2 Δt
⎛
⎝⎜
⎞
⎠⎟      (8.20) 
 89 
It produces trajectories that are identical to the original Verlet algorithm [438]: 
ri t + Δt( ) = 2ri t( )− ri t − Δt( ) +
1
m Fi t( )Δt
2 +O Δt 4( )                (8.21) 
Therefore, the leapfrog algorithm is (locally) a third order method and it is time-
reversible. The advantage of the leapfrog algorithm with respect to the original Verlet 
algorithm is that the velocities are calculated explicitly. The disadvantage is that the 
velocities are not calculated at the same time of the positions, therefore kinetic energy 
contributions to the total energy cannot be calculated at the same time as the new 
positions are obtained. The equations of motion are modified for temperature 
coupling and pressure coupling, both of which are described in following sections. 
8.2.3.3 Periodic boundary conditions 
The system sizes that can be simulated using MM-based approaches are limited due to 
the restriction from the computational power. Therefore, periodic boundary conditions 
(PBC) are employed to mimic the properties of bulk system and avoid artificial 
surface effects, by infinitely replicating the box containing the system in all three 
directions. Thus, the box is surrounded by images of itself with the same size, shape 
and content (Figure 8.3A). All these boxes are separated by open boundaries so that 
particles can freely enter or leave any box. As a result, if atoms leave the box, their 
images simultaneously enter the box through the opposite side. 
 
For short-range interactions in Eq. (8.15) (e.g. London interaction), the minimum-
image convention is used together with PBC to ensure that each particle interacts at 
most with only one image of every other N - 1 particles. A cutoff distance, rcut, can be 
introduced to save computational resources, so that interactions between particles (rij) 
beyond the cutoff range (rij > rcut) are excluded. If the cutoff is not longer than half of 
the shortest box vector, then in order to calculate the interaction of an individual 
particle i with all the replicas of another particle j it is sufficient to consider only the 
closest image among the particles j to i. 
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Figure 8.3: 2D illustrations of periodic boundary condition (A) and neighbor list 
(B). In (A), when an atom moves out of the simulation box, an image particle moves 
in from the opposite side to replace it. In (B), the neighbor lists on its construction, 
later, and too late are shown from left to right. Interacting atoms (white circles) and 
atoms in the neighbor list (gray filled circles) of atom i are indicated. The neighbor 
list must be reconstructed before any unlisted atoms (black filled circles) have entered 
the range of rcut. 
8.2.3.4 Neighbors list 
Although the use of cutoff avoids expensive calculations, it is still time consuming to 
examine all the distinct pairs within a given biological systems to find the ones that 
are within the cutoff. The “neighbor list” technique was introduced by Verlet to 
improve the computing speed. The cutoff rcut gives a sphere of radius rcut around atom 
i within which we can find all the atoms j that interact with i (see Figure 8.3B). A 
larger range rlist is further defined to identify a larger sphere around atom i for 
determining a list of neighbor atoms as possible interacting atoms. In practice, only 
pairs between i and the atoms appearing in the corresponding neighbor list are 
examined for the force computation. Therefore, not all pairwise interactions are 
tested. The neighbor lists have to be reconstructed rather frequently, before an 
unlisted atom can enter the interaction range rcut of the corresponding atom. 
Therefore, the simulation setup requires finding the best compromise between a small 
value νlist of the updating frequency of the neighbor list, and a small value of rlist, 
without compromising accuracy. Both the typical velocities of the atoms in the 
system, and the computing time needed to evaluate the interactions of all the pairs 
defined by rlist are the parameters to take into account to find the best values for νlist 
and rlist. 
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8.2.3.5 Long-range interactions 
Coulomb (electrostatic) interactions play an important role in biomolecular systems. 
Compared to covalent and London interactions (short-range interactions) in the force 
fields, their range is relatively long [435]. The difference between short- and long-
range interactions is the spatial extent of the potential. The London interaction energy 
between two molecules with a distance r is proportional to r-6. Therefore, it can be 
approximated reasonably well by introducing a certain cutoff distance to speed up 
performance. In contrast, the long-range interaction energy between two charged 
molecules is proportional to r-1 and the cutoff approximation is too poor and would 
bring to unsatisfactory inaccuracies. Moreover, due to their long-range nature, such 
interactions should be summed over all the periodic images and therefore a 
straightforward calculation appears computationally prohibitive.  
 
In order to deal with this issue, special techniques have been developed. The Ewald 
summation method introduced by Ewald [440] is of particular importance in this 
context. It takes advantage of the crystal symmetry imposed to the system by the PBC 
along with the idea to perform the calculations in the reciprocal. The details of the 
algorithm are described below. 
 
Consider a neutral system in a lattice made up of N particles with charges q1, q2, …, 
qN, at positions r1, r2, …, rN. The real space lattice vectors are a1, a2, and a3. All the 
particles are assumed to be spherically homogeneous (point-like in biomolecular 
systems). The problem is to calculate the Coulomb energy experienced by particle i in 
the presence of all the other particles in the system. Under PBC, the Coulomb energy 
of the system is defined by: 
    (8.22) 
where the sum over n is the sum over lattice vectors n=n1a1+ n2a2+ n3a4, (n1, n2, n3 ∈ 
Z) and ϕ(ri) is the Coulomb potential.  
The Ewald summation introduces a localized "screening" charge density in spherical 
Gaussian distribution of width , which is centered at each point charge, of 
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equal magnitude and opposite sign. The screening charge density ρS(r) is a sum of the 
local densities: 
   (8.23) 
The Coulomb potential ϕ(ri) can then be rewritten as 
   (8.24) 
where ϕS(ri) is the electrostatic potential generated by ρS. With this partitioning, the 
ϕreal(ri) summation can converge rapidly in the real space with a suitable choice of the 
width of the Gaussian distributions, while the last contribution ϕrecip(ri) corresponds 
to the electrostatic potential of the periodic charge density -ρS(r) and therefore can be 
more easy calculated in the reciprocal space. In fact, according to Poisson’s equation: 
        (8.25) 
which can be rewritten in the Fourier space: 
    (8.26) 
where m is the reciprocal lattice vector. Fourier transforming Eq. (8.23), substituting 
it into Eq. (8.26) and anti-Fourier transforming back to the real space we get [441]: 
       (8.27) 
where V is the volume of the lattice. 
The solution for ϕreal(ri) is: 
        (8.28) 
where erf is the complementary error function.  
Collecting all the terms, the final Coulomb potential energy can be therefore written 
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as: 
 
 
                   (8.29) 
where the last term J(D,P,ε’) has been introduced to correct for non-uniform field 
associated with a macroscopic crystal in a dielectric continuum [442,443], depending 
on the dipole moment of the unit cell D, the shape of the macroscopic boundary P, 
and the external dielectric constant ε’.  
In computing the direct sum, the parameter β can be exploited to reduce the real-space 
sum from O(N2) to O(N) by employing a cutoff approach, while the reciprocal sum is 
approximated numerically by using Particle-Mesh (PM) methods (such as the PM 
Ewald (PME) [444] or Particle-Particle PM (PPPM) [445]), taking advantage of the 
fast Fourier transform (FFT) algorithm.  
Biomolecules are usually not charge-neutral. To treat these systems with an Ewald 
method, one could either add counterions to neutralize the system or just introduce a 
uniform neutralizing background. In fact, it has been shown that adding counterions 
will lead to a better description of the dynamics of biomolecules during the simulation 
than using the uniform neutralizing background, although the difference might not be 
significant [446]. 
8.2.3.6 Temperature and pressure control 
MM-based simulations can be performed in different thermodynamic ensembles 
characterized by the control of constant thermodynamic quantities, including the 
number of particles (N), the pressure (P), the temperature (T), the volume (V), the 
total energy (E) and the chemical potential (µ) of the system. The simplest is the 
microcanonical ensemble (also named NVE because N, V, and E are kept constant). 
However, the conditions of NVE ensemble do not fit those in which experiments are 
usually made. A more meaningful description of biological system is achieved by 
simulating the system at constant P and T, that is the so-called isothermal-isobaric 
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(NPT) ensemble. In such simulations, thermostat and barostat algorithms are required 
to control P and T of the system. The most widely used thermostat and barostat 
approaches are described below. 
 
Berendsen thermostat 
Experimentally, to maintain the temperature, the system is coupled to an external heat 
bath with fixed temperature T0. In the Berendsen approach [447], the thermostat 
behavior is mimicked by rescaling the velocities of the particles at each step, such that 
the rate of change of the temperature is proportional to the difference in temperature: 
      (8.30) 
where τ is the coupling parameter determining how tightly the bath and the system 
are coupled together. This method produces an exponential decay of the system’s 
temperature to the target one T0. The change in temperature between successive time 
steps (δ(t)) is: 
    (8.31) 
Thus, the scaling factor for the velocities is: 
    (8.32) 
In practice, τ is used as an empirical parameter to adjust the strength of the coupling. 
It has to be chosen with care. In the limit τ → ∞, the Berendsen thermostat is inactive 
and the run is sampling a NVE ensemble. The T fluctuations will grow until they 
reach the appropriate value of an NVE ensemble. However, they will never reach the 
appropriate value for a canonical ensemble. On the other hand, too small values of τ 
will cause unrealistically low temperature fluctuations. If τ is chosen equal to the time 
step δt, the Berendsen thermostat is nothing else than a simple velocity scaling. 
Values of τ ≈ 0.1 ps are typically used in MD simulations of condensed-phase 
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systems. The Berendsen thermostat is extremely efficient for relaxing a system to the 
target temperature, but once your system has reached equilibrium, it might be more 
important to probe a correct canonical ensemble. 
 
Nóse-Hoover thermostat 
This method to control the temperature, based on an extended Lagrangian approach, 
was originally introduced by Nóse [448] and subsequently developed by Hoover 
[449]. It turns out to be more effective in correctly sampling velocities of a canonical 
ensemble than the Berendsen thermostat, which is instead suitably used for efficiently 
relaxing a system to a target temperature. The idea of the Nóse-Hoover thermostat is 
to modify the equation of motions to include a non-Newtonian term within the 
Lagrangian formulation of the mechanical system in order to maintain the total kinetic 
energy constant. This term is a friction factor used to control particle velocities. This 
friction factor is actually the scaled velocity, v(ξ), of an additional and dimensionless 
degree of freedom ξ. The additional degree of freedom has an associated "mass", 
which effectively determines the strength of the thermostat. The equations of motions 
obeyed by this additional degree of freedom guarantee that the original degrees of 
freedom sample a canonical ensemble. 
 
Andersen barostat 
Among the many classes of pressure control approaches, the Andersen barostat have 
been the most used over past decades. Below I present a short description of Andersen 
barostat [450] and an extended version of it, the Parrinello-Rahman barostat [451] that 
was employed in the NPT simulations of this thesis. 
 
The algorithm of Andersen barostat [450] is similar to the Nóse temperature coupling. 
It uses the extended system scheme that involves coupling the system to an external 
variable V (the volume of the simulation box). The position ri is then scaled as  
      (8.33) 
The Lagrangian of the scaled system can be written as: 
  (8.34) 
M and p0 are constants. The last two terms represent the kinetic energy and potential 
ρi = ri /V
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energy associated with V, respectively. A physical interpretation of the last two 
additional terms would be: Assume the system is simulated in a container and can be 
compressed by a piston. Thus, they are represent the kinetic energy and potential 
energy acting on the piston, respectively. The parameter M, the “piston mass”, is a 
user supplied parameter. A low M will result in rapid box size oscillations, which are 
not damped very efficiently by the motions of the molecules, while a low M will give 
rise to a slow adjustment of the volume. Andersen recommends the M be chosen to 
make the response time approximately equal to that for a sound wave to cross the 
simulation box.  
 
Parrinello-Rahman barostat 
The Andersen barostat does not allow the simulation box to change its shape. To 
overcome this problem, Parrinello and Rahman [451] extended the Andersen method 
to enable a variable simulation box shape. In the Parrinello-Rahman barostat, a time-
dependent metric tensor is introduced which allows the volume and the shape of the 
simulation box to vary with time. Basically, the box vectors are set to follow an 
equation of motion, and the equations of motion of the particles are also changed as in 
the Andersen barostat. 
The simulation box is a (unit) cell of a crystal system (due to the imposition of the 
PBC) and therefore it can be completely described by three vectors a, b, and c. It can 
have an arbitrary shape and therefore the vectors can have different lengths and 
arbitrary mutual orientations. Define a 3 × 3 matrix, h, whose columns are these three 
vectors. The box volume is given by: 
    (8.35) 
The position ri of a particle can be written in terms of h and a column vector si, with 
components ξi, ηi, and ζi as: 
    (8.36) 
with 0≤ ξi, ηi, ζi ≤1. The square of the distance between particle i and j is given by: 
         (8.37) 
  
V = deth = a⋅ b × c( )
  
ri = hsi = ξia +ηib+ζic
rij2 = sijTGsij
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where the metric tensor G=hTh. Using the latter notation, the Lagrangian of the scaled 
system can be written as: 
   (8.38) 
Derivation of the equations of motion for the Parrinello-Rahman barostat system is 
similar to the case of the Andersen barostat. 
8.2.3.8 Monte Carlo simulation 
Just as gaming in the casino of Monte Carlo rests upon the statistical properties of 
random events, MC-based methods are stochastic techniques. In contrast to the 
previously described MD approaches, the MC-based methods explore the 
configurational space of the system without any regard of the time relations between 
the different configurations. The MC approach generates a trajectory of 
configurations, but each step depends only on the previous configuration (Markov 
chain). To pass from the step n to the n+1 a random configuration is generated, often 
the randomization is related to the movement of an atom, or the rotation about one 
bound. These variations can be more than one for each step. The probability that the 
new state n+1 will be accepted is: 
       1   if E(n+1) < E(n) 
exp(-β ∆E)  if E(n+1) ≥ E(n) 
where E is the total energy of the system and β is the Boltzmann constant. After the 
acceptance or rejection of a move, the value of the property of interest is calculated. 
The results of many such steps are collated. Once sufficient sampling has been 
achieved, an accurate average value of this property can be obtained. 
One attractive aspect of MC simulations is that only the potential energy is normally 
used in stepping through configurations. Unlike MD simulations, MC simulations do 
not solve Newton’s equations of motion and do not need to calculate forces (although 
some biased MC approaches do utilize force data). This allows for much more 
efficient calculations, which can lead to great speedups of orders of magnitude in the 
sampling of equilibrium properties [436].  
However, there are a number of issues that hamper the use of MC simulations with 
large biomolecules [436]. One issue is that it is difficult to define efficient moves for 
macromolecules that change the configuration in a sufficiently large magnitude but 
  
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also avoid generating energetically infeasible configurations. Conventional MC 
methods are inefficient for exploring the configurational space of large biomolecules 
when compared to MD simulations [452]. However, some work has eased this issue 
for proteins [453-456]. Another main issue is performing MC simulations of proteins 
in explicit solvent. Because any move that significantly alters the internal coordinates 
of the protein without also moving the solvent molecules will likely result in a large 
overlap of atoms and thus the rejection of the move. This implies that the sampling 
will be inefficient under these conditions. MC simulations using implicit solvent do 
not suffer from these drawbacks. In addition, MC methods give no dynamical 
information about the time evolution of structural events. Last but not least, there is a 
lack of general, good, freely available programs for MC simulations of proteins 
because the choice of MC moves and acceptance criteria vary for one specific 
problem to another. 
All of these issues might be resolved by combining specific MD moves in a MC 
simulation, which allows great flexibility in the approach to a specific problem [436]. 
Combined MC/MD protocol has been employed in the work of this thesis to explore 
the protonation state space for protein complex in the gas phase. Details of the 
protocol will be described here in the following section. 
8.2.3.9 Hybrid Monte Carlo/molecular dynamics protocol 
To investigate the protonation state space of peptides and proteins in the gas phase, 
MC based protocols have been proposed [457]. These schemes suppose that the 
protein structure does not change with the protonation state and they usually assume 
that the (average) NMR generated or the crystallographic structures are a good 
approximation to the gas-phase structures. This may be generally true for the protein 
backbone, in particular cases, but does not for side chains. The latter undergo a wide 
reorganization in the course of the dehydration process. This event has been well 
documented by both theoretical [63,303,458-460] and experimental [202,461] works. 
The side chains and in particular the most polar ones interact with the surrounding 
water molecules in the biological environment. When these molecules are not any 
more available (into the gas-phase environment), the lost hydrogen bonds formed 
with water molecules can be compensated only by new intramolecular interactions 
that bring to a collapse of the side chains onto the protein surface. Other factors have 
to be considered in addition to the hydrogen bonds formation. In fact the Coulomb 
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interaction, in a low dielectric medium like vacuo, becomes stronger and thus must be 
taken into account for the estimation of the correct rearrangement representation. The 
hydrogen bond-driven side chain rearrangement and the long-range Colombian 
interactions are strongly related. It can be supposed that given a certain protonation 
patter, the side chains will optimize their geometry both to increase the number of 
hydrogen bonds and optimize the long-range forces. This easily predictable 
consideration needs a strong effort to be properly investigated. In fact, when a 
protonation state analysis is performed both the configurational and protonation state 
space of the system must be considered. 
To tackle the problem described above, we have used a hybrid MC/MD scheme [68], 
originally developed for single protein ESI-MS structural predictions. A flow chart 
describing the MC/MD protocol for protonation state space exploration is reported in 
Figure 8.4. The initial gas-phase charge distribution is randomly generated by 
following the protocol used in ref. [68]. For each protonation state considered, a 1 ns-
long MD simulation at 400 K was performed to allow for side-chain reorganization. 
The resulting trajectory is split into 60 equally spaced time windows. In each window 
the geometry of the lowest energy conformation is optimized using conjugate gradient 
geometry optimization. The energy of the conformer with the lowest value among the 
60 optimized structures is recalculated with the gas-phase basicity (GB) corrected 
force field (see Chapter 6 for details) and compared with that of the previous lowest 
energy (reference) protonation state (for the first loop the structure is always 
accepted). If the energy of the current protonation state is lower than the one of the 
reference protonation state, the current protonation state would be the new reference, 
i.e. the “lowest energy” protonation state, otherwise the protonation state would be 
defined based on a Metropolis test. To start the new loop, an MC step is performed on 
the current reference protonation state. The MC step consists of the deprotonation of a 
randomly selected protonated ionizable residue (neutralization of an ionized basic site 
or ionization of a neutral acidic site) and the protonation of another randomly selected 
protonated ionizable residue (ionization of a neutral basic site or the neutralization of 
an ionized acidic site), resulting in a proton shift between two residues. This 
procedure maintains the total charge fixed. The iterative procedure stops when no new 
protonation states are generated in ten consecutive iterations. For each value of net 
charge, this procedure converges in a relatively small number of MC steps (from 1000 
to 3000).  
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Figure 8.4: Flow chart of the hybrid MC/MD protocol in the current work for 
determining the lowest energy protonation state. In general, the starting structure 
of protein complex for gas-phase calculations is generated from MD simulations in 
water (light blue background, steps 1-3). After selecting representative starting 
structures and a random generation of initial protonation states, structures for low 
energy gas phase protonation states are derived in an iterative procedure (blue 
background) beginning with high-temperature MD simulations in the gas phase. 
Subsequently, the lowest energy conformation within equally spaced time windows is 
obtained by geometry optimization. The optimized structures are then employed in 
the MC procedure using GB corrected force field energies and a Metropolis test to 
define the current lowest energy protonation state. For the next iteration, a new 
protonation state is generated. Convergence is reached when the program fails to 
generate a new protonation state for ten consecutive iterations. The procedure 
converges in a relatively small number of MC steps as was tested in our current work 
on a protein complex and previous calculations of single similar-sized proteins [68]. 
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Appendices 
Appendix A1 Supplementary materials for Chapter 2 
 
 
Figure A1: Cell cycle and cell-cycle control. Cell cycle is divided into four distinct 
phases: S (DNA replication), M (mitosis) and two gap phases (G1 and G2) that 
separate the M and S phases. G0 represents exit from the cell cycle. The cell cycle is 
regulated by the dynamic interactions of highly coordinated enzymatic proteins to 
ensure genomic fidelity. Cells first enter the cell cycle after receiving mitogenic 
signals. These are processed in cells by various signal transactivation pathways that 
include molecules, such as rat sarcoma homolog (RAS). These pathways activate the 
cyclin D-dependent kinases, CDK4 and CDK6, via increased expression of cyclin D 
and by triggering release from inhibitory proteins, such as p15INK4B and p16INK4A. 
p21CIP1 and p27KIP1 proteins. In G1, retinoblastoma protein (Rb) is initially 
phosphorylated by cyclin D/CDK4(6) complexes, which leads to disruption of the 
complex with histone deacetylates (HDAC) and abrogation of the Rb-dependent 
inhibition of E2F transcription factors. E2F transcription factors are then released 
from the partially phosphorylated Rb and promote transcription of genes necessary to 
progress through the G1/S checkpoint. Rb is further phosphorylated in late G1 by 
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cyclin E/CDK2 complexes, enabling E2F transcription factors to express genes 
required for DNA synthesis. After entry into the S phase, a hyperphosphorylated state 
of Rb is maintained by the activities of cyclin A/CDK2, cyclin A/CDK1 and cyclin 
B/CDK1 complexes. At the end of mitosis Rb proteins are dephosphorylated by 
phosphatases allowing interaction with transcription factors E2F and DP to prevent 
unregulated cell proliferation. The cell cycle is negatively regulated by members of 
the p15INK4B, p16INK4A, p21CIP1 and p27KIP1, and by the pharmacological inhibitors 
Palbociclib, 219476, P276-00, Seliciclib, Dinaciclib and CVT-313. The figure is 
adapted from ref. [462]. 
Appendix A2 Supplementary materials for Chapter 4 
A2.1 Construction of CDK2/2Mg(II) model (model B)  
The available crystal structures of cyclin A/CDK2 in complex with ATP and 
phosphorylated at T160 contain a single divalent metal ion [226]. The kinase domain 
of CDK2 shares the same domain architecture [226] and 32% of sequence identity 
with the correspondent domain in the protein kinase A (PKA) from mouse (PDB ID: 
1ATP [230], Figure 4.2), for which an X-ray structure, including two metal ions and 
coordinated water molecules, is available. Hence, we have predicted the location of 
additional Mg(II) and water molecules in CDK2 by superimposing the two structures 
on the kinase domains of CDK2 (residues 5-209) and PKA (residues 44-245) using 
PyMOL program (Molecular Graphics System, Version 1.3, Schrödinger LLC). 
A2.2 p27KIP1 peptide structural prediction 
200 models of the p27KIP1 C-terminal peptide were generated using the MODELLER 
9v9 package [252]. 64 models turned out to have 90% residues or more in the most 
favored regions of Ramachandran plot [270]. We selected the model that shows the 
lowest difference (in terms of backbone RMSD, 1.1 Å) compared with the p27KIP1’s 
crystal structure [90]. 
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Figure A2: Sequence logo plot represent normalized amino acid frequencies for 
±7 amino acids from the phosphorylation site of 63 local-sequences of 38 CDK2 
in vivo substrates reported in Table A1. This figure was generated using WebLogo 
[463]. 
 
Figure A3: Primary sequences of p27 and p27’ peptides. p27 is a C-terminal 
p27KIP1 peptide we used in this work. p27’ is a crystallized peptide segment of p27KIP1 
(PDB ID: 2AST [90]). The letters in bold represent the phosphorylation sites. 
 
 
Figure A4: Superposition of predicted models of cyclin A/CDK2•HHASPRK 
(A), cyclin A/CDK2•SIRT2 (B) and cyclin A/CDK2•p27KIP1 (C) with cyclin 
A/CDK2•HHASPRK X-ray structure (PDB ID: 1QMZ [55]). The cartoon 
representations of CDK2, cyclin A, and SIRT2 (or p27KIP1) are colored in blue, 
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orange, and green, respectively. The peptide substrate in crystal structure is colored in 
cyan. 
    
 
 
Figure A5: Close-up view of Mg(II) binding sites of cyclin A/CDK2•HHASPRK 
from crystal structure [78] (A) and predicted model of cyclin 
A/CDK2•HHASPRK (B), cyclin ACDK2•SIRT2 (C) and cyclin A/CDK2·p27KIP1 
(D). CDK2 residues are represented by blue stick. ATP carbon atoms are colored in 
grey. Mg(II) and water molecule are indicated by green and red spheres, respectively. 
The coordination distances between Mg(II) and its ligands (ATP, N132, D145 and a 
water molecule) are also labeled. The average coordination distances in predicted 
model and crystal structure are 1.8 Å and 2.1 Å, respectively. 
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Figure A6: Superposition of cyclin A/CDK2•p27KIP1 with PKA•ATP•2Mn(II) 
crystal structure (PDB ID: 1AST [230]). The second Mn(II) in PKA is indicated by 
cyan sphere. The cartoon representations of CDK2, cyclin A, and p27KIP1 are colored 
in blue, orange, and green, respectively. PKA is colored in cyan. PKA residues are 
labeled with prime. 
 
Table A1: Information on human CDK2 substrates (38 in vivo substrates and 63 
phosphorylation sites) searched from PhosphoSitePlus [464] and Kinase Substrate 
Database (http://www.kinasource.co.uk/).  
Index Protein  UniProtKB  P site Site sequence Reference 
1 ATRIP Q8WXE1 S224-p APSVSHVSPRKNPSV [465] 
2 BRCA1 P38398 S1497-p EPGVERSSPSKCPSL [466] 
3 CCNA2 P20248 S154-p PMDGSFESPHTMDMS [467] 
4 CCNE1 P24864 T395-p PLPSGLLTPPQSGKK [468,469] 
5 CCNE1 P24864 S399-p GLLTPPQSGKKQSSG [468,470] 
6 Cdc25C P30307 S214-p SRSGLYRSPSMPENL [471] 
7 CDKN2D P55273 S76-p -QDTSGTSPVHDAAR [472] 
8 CDX2 Q99626 S283-p RSVPEPLSPVSSLQA [473] 
9 CROCC iso2 Q5TZA2-2 S763-p APRPVPGSPARDAPA [474] 
10 Ctip Q99708 T847-p FRYIPPNTPENFWEV [475] 
11 DLG1 Q12959 S158-p FVSHSHISPIKPTEA [476] 
12 DLG1 Q12959 S443-p FLGQTPASPARYSPV [476] 
13 EZH2 Q15910 T345-p LTAERIKTPPKRPGG [477] 
14 FOXM1 iso2 Q08050-2 T596-p ETLPISSTPSKSVLP [478] 
15 FOXO1A Q12778 S249-p EGGKSGKSPRRRAAS [479,480] 
16 HIRA P54198 T555-p LSPSVLTTPSKIEPM [481] 
17 HR6A P49459 S120-p LDEPNPNSPANSQAA [482] 
18 ID3 Q02535 S5-p ---MKALSPVRGCYE [40] 
19 LIG1 P18858 S51-p GVVSESDSPVKRPGR [483] 
20 LIG1 P18858 S76-p EEEDEALSPAKGQKP [483] 
21 LIG1 P18858 S91-p ALDCSQVSPPRPATS [483] 
22 LIG3 P49916 S210-p TTTGQVTSPVKGASF [484] 
23 NPAT Q14207 T1270-p SDLPVPRTPGSGAGE [485] 
24 NPAT Q14207 T1350-p ISRTTSATPLKDNTQ [485] 
25 ORC2 Q13416 T116-p LASELAKTPQKSVSF [486] 
26 ORC2 Q13416 T226-p SAPVGKETPSKRMKR [486] 
27 p21Cip1 P38936 S130-p SGEQAEGSPGGPGDS [487] 
28 p27Kip1 P46527 T187 NAGSVEQTPKKPGLR [488,489] 
29 p63 Q9H3D4 T491-p PQQRNALTPTTIPDG [490] 
30 p73 O15350 T86-p AASASPYTPEHAASV [491] 
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31 PELP1 Q8IZL8 S991-p PALPPPESPPKVQPE [492] 
32 PLZF Q05516 S197-p SFGLSAMSPTKAAVD [493] 
33 PLZF Q05516 T282-p RGKEGPGTPTRSSVI [493] 
34 PPP1CA P62136 T320-p NPGGRPITPPRNSAK [494] 
35 PTHrP P12272 T121-p YKEQPLKTPGKKKKG [495] 
36 PTPN2 iso2 P17706-2 S304-p LSPAFDHSPNKIMTE [496] 
37 Rb P06400 S249-p AVIPINGSPRTPRRG [497] 
38 Rb P06400 T252-p PINGSPRTPRRGQNR [497] 
39 Rb-like 2 Q08999 S413-p VRYIKENSPCVTPVS [498] 
40 Rb-like 2 Q08999 T417-p KENSPCVTPVSTATH [498] 
41 Rb-like 2 Q08999 S639-p DEICIAGSPLTPRRV [498] 
42 Rb-like 2 Q08999 T642-p CIAGSPLTPRRVTEV [498] 
43 Rb-like 2 Q08999 S662-p GLGRSITSPTTLYDR [498] 
44 Rb-like 2 Q08999 S688-p RLFVENDSPSDGGTP [498] 
45 Rb-like 2 Q08999 T694-p DSPSDGGTPGRMPPQ [498] 
46 Rb-like 2 Q08999 S952-p DSRSHQNSPTELNKD [498] 
47 Rb-like 2 Q08999 S1044-p YPFVRTGSPRRIQLS [498] 
48 Rb-like 2 Q08999 S1068-p HKNETMLSPREKIFY [498] 
49 Rb-like 2 Q08999 S1080-p IFYYFSNSPSKRLRE [498] 
50 Rb-like 2 Q08999 T1097-p SMIRTGETPTKKRGI [498] 
51 Rb-like 2 Q08999 S1112-p LLEDGSESPAKRICP [498] 
52 RbBP1 P29374 S864-p RKILGQSSPEKKIRI [499] 
53 RbBP1 P29374 S1007-p QHNFSVASPLTLSQD [499] 
54 RPL12 P30050 S38-p KIGPLGLSPKKVGDD [494] 
55 SIRT2 Q8IXJ6 S368-p PNPSTSASPKKSPPP [44] 
56 Smad3 P84022 T8-p MSSILPFTPPIVKRL [500] 
57 Smad3 P84022 T179-p PQSNIPETPPPGYLS [500] 
58 Smad3 P84022 S213-p NLSPNPMSPAHNNLD [500] 
59 TFCP2 Q12800 S309-p SLGEGNGSPNHQPEP [501] 
60 SMRT Q9T618 S1259-p TRIIGEDSPSRLDRG [42] 
61 SMRT Q9T618 T1463-p EGSITQGTPLKYDTG [42] 
62 SMRT Q9T618 S1487-p DVRSLIGSPGRTFPP [42] 
63 NBS1 Q9NX02 S432-p RIPNYQLSPTKLPSI [502] 
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Appendix A3 Supplementary materials for Chapter 5 
 
 
Figure A7: Structural models of the lowest interaction energy docking structure 
of SIRT2 in complex with cyclin A/CDK2 in the largest cluster. The cartoon 
representations of CDK2, cyclin A, and SIRT2 are colored in blue, orange, and green, 
respectively. The CT of SIRT2 is colored in pink. 
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Table A2: Templates for SIRT2 homology models. The PDB ID, template sequence, 
target sequence, template-target identity and reference are given.  
 
N-terminal region (NT) 
 
 
 
C-terminal region (CT) 
 
 
 
 
 Segment 
ID 
PDB ID Template 
sequence 
Target sequence Identity 
(%) 
Ref. 
NT 
 
1 2CX6 D16-D36 D2-D23 55 [503] 
2 2OVJ D424-L434 D2-D23 48 [504] 
3 3PSE M1-L7 M1-L5 86 [505] 
4 2FCG D26-L31 D2-L7 100 [506] 
5 2HEK F295-E304 F8-D23 50 [507] 
6 3PCO R195-T201 R5-T11 57 [508] 
7 1VE2 K169-E174 K18-D23 70 [509] 
8 2WSP Q337-L342 Q17-L22 100 [510] 
9 3DJA L179-G190 L4-R20 58 [511] 
10 1U7J M1-R5 M1-R5 80 [512] 
11 1PWX L211-E216 L14-E19 83 [513] 
12 3FMC T239-R347 T11-R20 80 [514] 
13 1G0D G445-R450 G15-R20 100 [515] 
CT 
 
 
14 3HJT Q60-I65 Q318-V323 83 [516] 
15 1V8H P65-P73 P324-P332 78 [517] 
16 2DFX P58-P63 P332-P337 83 [518] 
17 1XG2 P105-A110 P338-A343 83 [519] 
18 1U3O R58-Q66 R344-Q352 78 [520] 
19 2CUI G44-T50 G322-T328 86 [521] 
20 1YPZ K119-K125 K334-K340 86 [522] 
21 2X1L G373-P379 G320-P326 71 [523] 
22 1YU3 S216-S222 S329-S335 100 [524] 
23 1YQ2 S789-A800 S319-A330 67 [525] 
24 3RQR A2913-Q2924 A339-Q352 57 [526] 
25 1WQL Q412-N419 Q318-N325 88 [527] 
26 1J3L A113-K120 A330-K340 64 [528] 
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Table A3: Average RMSD values of backbone atoms of the CC of SIRT2 in a total of 
240 ns MD simulations by using various histidine protonation states, relative to those 
in the X-ray structure. The three possible protonation states of histidine are 
represented by HID (Nδ nitrogen atom protonated), HIE (Nε nitrogen atom 
protonated) and HIP (both Nδ and Nε nitrogen atoms protonated). The possible 
combinations (a-x) are 24. The standard deviations (SD) are also reported. The chosen 
configuration for MD simulations is state j with the lowest RMSD value compared 
with others. 
  
Histidine Protonation state 
 a b c d e f g h 
H74 HIE HIE HIE HIE HIE HIE HIE HIE 
H90 HIE HIE HIE HIE HIE HIE HIE HIE 
H112 HIP HIP HIP HIP HIP HIP HID HID 
H150 HID HID HIE HIE HIP HIP HID HID 
H157 HIP HIE HIP HIE HIP HIE HIP HIE 
H165 HIP HIP HIP HIP HIP HIP HIP HIP 
H312 HID HID HID HID HID HID HID HID 
RMSD (nm) 0.24±0.03 0.23±0.03 0.30±0.08 0.21±0.03 0.23±0.03 0.22±0.03 0.26±0.02 0.27±0.05 
         
 i j k l m n o p 
H74 HIE HIE HIE HIE HIE HIE HIE HIE 
H90 HIE HIE HIE HIE HIE HIE HIE HIE 
H112 HID HID HID HID HIP HIP HIP HIP 
H150 HIE HIE HIP HIP HID HID HIE HIE 
H157 HIP HIE HIP HIE HIP HIE HIP HIE 
H165 HIP HIP HIP HIP HIP HIP HIP HIP 
H312 HID HID HID HID HIP HIP HIP HIP 
RMSD (nm) 0.29±0.04 0.20±0.04 0.24±0.03 0.22±0.04 0.23±0.03 0.24±0.04 0.21±0.03 0.24±0.04 
         
 q r s t u v w x 
H74 HIE HIE HIE HIE HIE HIE HIE HIE 
H90 HIE HIE HIE HIE HIE HIE HIE HIE 
H112 HIP HIP HID HID HID HID HID HID 
H150 HIP HIP HID HID HIE HIE HIP HIP 
H157 HIP HIE HIP HIE HIP HIE HIP HIE 
H165 HIP HIP HIP HIP HIP HIP HIP HIP 
H312 HIP HIP HIP HIP HIP HIP HIP HIP 
RMSD (nm) 0.27±0.04 0.22±0.03 0.27±0.06 0.26±0.04 0.22±0.04 0.21±0.03 0.26±0.04 0.22±0.04 
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Appendix A4 Supplementary materials for Chapter 6 
A4.1 MD simulations of hIns2 in water 
The structure of hIns2 appeared to be equilibrated already after ~10 ns as indicated by 
plots of the backbone heavy atoms root mean square deviations (RMSD) as a function 
of simulated time (Figure A8). The structure whose backbone is the closest to that of 
the average conformation (RMSD=0.6 Å) was extracted from the trajectory at a time 
between 10 and 100 ns to be used as the starting structure for gas-phase MD 
simulations. The B-factor and monomer-monomer interaction analyses of the 
complex in water were presented in Figure A8D and in Figures A8E and A8F, 
respectively. Averages of structural properties were reported in Table A5. 
 
A4.2 Determination of simulation parameters for MC/MD scheme 
We optimized the parameters (temperature and sampling time length) in the hybrid 
Monte Carlo/Molecular Dynamics (MC/MD) scheme for the exploration of the 
protonation state space (see next section for a more detailed description). To this end, 
1 ns long MD simulations in gas phase were carried out on hIns2 for a randomly 
generated protonation state with temperatures of 300, 350 and 400 K. As the internal 
temperature of ions just emitted from droplets is associated with uncertainties, there 
is, up to now, no clear connection between simulation and experimental temperatures 
[529]. The RMSD plot of side chain atoms starts to fluctuate around an average value 
of 0.38±0.02 nm after 0.5 ns. Similar behavior was observed for longer simulations, 
including 2 and 3 ns (Figure A9), suggesting that the economical 1 ns long simulation 
has similar performance in covering a variety of conformations for a given 
protonation state. The structures for all tested temperatures are well conserved 
(RMSD<0.2 nm, Figure A9). A calculation of the root mean square fluctuations 
(RMSF) of side chain atoms (Figure A9B) as in ref. [530] and [531], leads us to the 
observation that, as expected, increasing the temperature increases the fluctuations of 
side chains. 
 
A4.3 Protonation state space exploration 
Zwitterionic states of the most probable protonation states are mostly retained, 
especially for low charge states (1+ to 5+, Figure A10B). However, they are totally 
abolished in high charge states (13+ to 15+, Figure A10B). Comparison of the lowest 
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energy protonation states indicates that some of the positive sites are very conserved 
across the majority of the charge states, i.e. the N-terminal residues (G1, F22, G52 
and F73), K50 and K101 (Table A4).  
 
A4.4 Determination of the energy cutoff for the identification of the most 
probable protonation states  
The data dispersion of the correlation between DFT energies and GB corrected force 
field energies (Figure 6.1B) indicates that the corrected force field allows to 
discriminate between high and low energy protonation states but not to appreciate 
small energy differences. To study the dispersion and obtain a reasonable cutoff 
criterion for the selection of the most probable protonation states, we adopted the 
following procedure. First, we identified the conformers (14 pairs out of 60 
conformers) whose DFT energy differences (ΔEDFT) are within 10 kJ/mol. Then, the 
corresponding GB corrected force field energy difference (ΔEcorr) in each pair of 
conformers was calculated (Table A8). We performed a statistical analysis of these 
force field energy differences in order to generate the probability distribution of 
conformers falling into different energy cutoffs (ΔEc). As shown in Figure A10A, 
most of the pairs of conformers (92.9 %) with ΔEDFT less than 10 kJ/mol fall within 
the ΔEc of 125 kJ/mol. 
 
Notice that the standard error (σ) of our linear regression between DFT and corrected 
force field (Figure 6.1B) is 63.7 kJ/mol. Thus, if we assume a normal distribution of 
the DFT energies around the estimation obtained from the corrected force field, there 
is a confidence of 68.2%, 95.4%, and 99.8% that the DFT energy is within σ, 2σ 
(127.4 kJ/mol) and 3σ (191.1 kJ/mol) from the estimation, respectively. The value of 
2σ is very close to the ΔEc (125 kJ/mol) derived from our protocol. Thus the 
discussion of protonation state properties presented in this work is based on a cutoff 
of 125 kJ/mol.  
 
A4.5 Calculation of the GBapp 
 
The GBapp,i of the i-th residue in a protein with total charge q is defined as [300] 
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  
GBapp,i = GBi − EFFi,q( ) − EFFi,q−1( )( )     (A.1) 
where GBi is the GB of the i-th amino acid in the gas phase and  is the 
energy of the protein with that residue protonated (non-protonated). In contrast to the 
original formulation developed for a coarse-grained representation of an unfolded 
protein [300], we included in the calculation of the GBapp all the classical energy 
terms included in a force field (FF). Vibrational corrections were not taken into 
account. The justification for this choice has been discussed previously in the 
literature [188,532]. 
 
A4.6 MD simulations in the gas phase of [hIns2]6+ with the most probable 
protonation states  
To check the sampling and convergence of the gas-phase MD trajectories, we 
calculated the cosine contents of the first two eigenvectors [261]. These account for 
63% of the backbone motions in the 0.075 ms long MD simulations. The cosine 
contents of the eigenvectors are 0.036 and 0.003 for the 0.075 ms long simulations. 
The values for two additional independent 0.035 ms long simulations and the 0.025 
ms long simulation with GROMOS 43a1 force field [310] are 0.127 and 0.197, 0.128 
and 0.110, and 0.231 and 0.268, respectively. 
 
In order to compare dynamic properties of different protonation states with the same 
charge state, MD simulations on five alternative lower energy protonation states (the 
most probable protonation states identified with a 125 kJ/mol cutoff) at the main 
charge state (q=6+), with charges located on different residues, have been carried out 
(Prot1 (the lowest energy protonation state) to Prot5, see Table A9).  
 
  
EFF(i,q )(EFF( i,q−1))
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Figure A8: MD simulation of hIns2 in water. (A) Primary sequence of hIns2 (each 
monomer consists of two chains of 21 and 30 amino acids linked by 2 disulfide 
bridges derived from a precursor molecule). The letters colored in red and blue 
represent chargeable sites of acidic (E, D, and C-terminal) and basic groups (R, K, H, 
and N-terminal), respectively, in solution. (B) hIns2 X-ray structure (PDB ID: 1MSO 
[321]). Monomer I (residues 1-51) and II (residues 52-102) are colored in blue and 
red, respectively. Each insulin monomer is composed of two peptide chains (A and B, 
colored in dark and light, respectively) linked by two disulfide bonds (shown as green 
sticks, sulfur atom in yellow). (C) Backbone atoms RMSD (in nm) from the starting 
conformation of hIns2 during the 100 ns long MD simulation in water. RMSD of the 
entire hIns2, of monomer I, and of monomer II are colored in black, red, and green, 
respectively. (D) B-factor (in Å2) plotted for Cα atoms of hIns2 from MD simulation 
and X-ray. The last 5 ns long MD trajectory of hIns2 has been used in the calculation 
of B-factors. The experimental values are obtained from the X-ray structure data of 
hIns2 [321]. Residues of chain AI and BI in monomer I are numbered 1-21 and 22-51, 
respectively. Residues of chain AII and BII in monomer II are numbered 52-72 and 
73-102, respectively. (E) Close-up view of inter-monomer interactions in the 
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representative model of hIns2. Hydrogen bonds are indicated by dashed black lines. 
(F) Intra-monomer hydrophobic interactions in monomers. The monomer I and II are 
indicated in cyan and green, respectively.  
 
  
Figure A9: Determination of simulation parameters for MC/MD scheme. (A) 
Superposition of the lowest energy configuration at 300 K (green) with that at other 
temperatures (blue). RMSDs (in nm) of backbone atoms are indicated in parentheses. 
(B) RMSFs (in nm) plotted for side chain atoms of hIns2 from 1 ns long MD 
simulations at various termperatures. (C) RMSDs (in nm) plotted for side chain atoms 
of hIns2 from MD simulations with various time lengths. The time lengths 1, 2 and 3 
ns are shown as black, red and blue, respectively. 
 
 
Figure A10: Protonation state space exploration. (A) Probability that a pair of DFT 
conformers with ΔEDFT less than 10 kJ/mol falls within ΔEc in the GB corrected force 
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field energies. The probability is calculated by counting the number of pairs falling 
within ΔEc. (B) The number of ionized residues (circles) in the most probable 
protonation states of the hIns2 as a function of the protein net charge (q). Standard 
deviation from the average is given as error bars. The minimum and the maximum 
numbers of possible ionized residues for each total charge are indicated by the green 
and the red lines, respectively. The vertical dashed blue line indicates the main charge 
state in ESI-MS [299]. 
 
Figure A11: 0.075 ms long MD simulation in the gas phase of [hIns2]6+. (A) 
Radius of gyration (Rg) of the entire hIns2, of monomer I, and of monomer II. (B) 
Center-of-mass (COM) distance between monomers. (C) COM distances between 
monomers and β-sheet region. (D) RMSD (in nm) from the starting conformations of 
hIns2. (E) Number of hydrogen bonds within the complex. (F) Number of hydrogen 
bonds between monomers. 
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Figure A12: The largest essential motions of the protein complex along the 
combined water-and-gas-phase trajectories obtained from the 0.01 µs long 
simulation in water and the 0.075 ms long simulation in the gas phase (A), along 
the trajectory from the converged part (0.055 to 0.075 ms) of the simulation in 
the gas phase (B), and along the trajectory from the entire 0.075 ms long 
simulation in the gas phase (C). The monomer I and II are presented as cyan and 
green trace models, respectively. The β-sheet regions are highlighted in orange. The 
fluctuations of the backbone atoms are depicted as red arrows. 
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Figure A13: Correlations between CCS and a variety of properties obtained 
from MD simulations in the gas phase of [hIns2]6+. (A) Radius of gyration (Rg) of 
the entire hIns2. (B) Solvent accessible surface area (SASA) of the entire hIns2. (C) 
The angle between the center of mass of monomer I – β-sheet region – monomer II. 
(D) Number of contact pairs between the carbon atoms of the monomers within 0.60 
nm. (E) Number of hydrogen bonds within the complex. (F) Number of hydrogen 
bonds between monomers. 
 
Figure A14: 0.035 ms long independent MD simulations in the gas phase of 
[hIns2]6+. (A) Models of [hIns2]6+ obtained from MD simulations in the gas phase 
(from left to right, at 0 µs, 5.31 µs, 20.52 µs and 34.2 µs). (B) Secondary structure 
analysis for [hIns2]6+. (C) The angle between the center of mass (COM) of monomer I 
– β-sheet region – monomer II. (D) CCS values. (E) Number of contact pairs between 
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the carbon atoms of the monomers within 0.60 nm. The figure captions are same with 
the ones used in Figure 6.3.  
 
 
Figure A15: 0.035 ms long independent MD simulations in the gas phase of the 
[hIns2]6+. (A) Models of [hIns2]6+ obtained from MD simulations in the gas phase 
(from left to right, at 0 µs, 7.68 µs, 19.68 µs, and 34.2 µs). (B) Secondary structure 
analysis for [hIns2]6+. (C) The angle between the center of mass (COM) of monomer I 
– β-sheet region – monomer II. (D) CCS values. (E) Number of contact pairs between 
the carbon atoms of the monomers within 0.60 nm. The figure captions are same with 
the ones used in Figure 6.3.  
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Figure A16: 0.025 ms long independent MD simulations with GROMOS force 
field in the gas phase of [hIns2]6+. (A) Models of [hIns2]6+ obtained from MD 
simulations in the gas phase (from left to right, at 0 µs, 7.89 µs, 19.6 µs, and 24.3 µs). 
(B) Secondary structure analysis for [hIns2]6+. (C) The angle between the center of 
mass (COM) of monomer I – β-sheet region – monomer II. (D) CCS values. (E) 
Number of contact pairs between the carbon atoms of the monomers within 0.60 nm. 
The figure captions are same with the ones used in Figure 6.3.  
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Table A4: The lowest energy protonation states for charge states from 1+ to 15+. The 
positive and negative charged residues are indicated by “+” and “-”, respectively. 
 1+ 2+ 3+ 4+ 5+ 6+ 7+ 8+ 9+ 10+ 11+ 12+ 13+ 14+ 15+ 
Number of charged amino acids 11 8 7 10 7 8 9 10 11 14 13 14 13 14 15 
N-terminal G1 + + + +  +  + + + + + + + + 
E4 -          -     
Q5            + + + + 
Q15          +    + + 
E17                
C-terminal N21 - - - - - - -         
N-terminal F22 +   + + + + + + + + + + + + 
Q25            +    
H26       + + +  + + + + + 
H31         + + + + + + + 
E34  -              
E42                
R43       + +  + +  + +  
K50 + + + + + +  + + + + + + + + 
C-terminal T51 -         -  -    
N-terminal G52 +  + + + + + + + + + + + + + 
E55   - -            
Q56            +   + 
Q66               + 
E68                
C-terminal N72 -        - -      
N-terminal F73 +  + + + +  + + + + + + + + 
Q76  +            +  
H77    + +  + + + + + + + + + 
H82  +    + +   + +  +  + 
E85  -              
E93                
R94       +  + + + + + + + 
K101 + + + + + + + + + + + + + + + 
C-terminal T102 -   -    -        
 
Table A5: Average structural properties of MD simulations in the gas phase of 
[hIns2]6+ with the lowest energy protonation state. From left to right: length of 
simulation (Length in µs); radius of gyration (Rg in nm); radius of gyration of 
backbone atoms (Rg,BB in nm); radius of gyration of monomer I (Rg,MI in nm); radius 
of gyration of monomer II (Rg,MII in nm); collision cross section (CCS in nm2); total 
surface area (SA in nm2); center-of-mass distance between monomers (COMP-P in 
nm); number of hydrogen bonds in protein-protein interface (HBP-P); number of 
hydrogen bonds in complex (HB); number of hydrogen bonds in complex (HB); 
number of contact pairs between the carbon atoms of the monomers defined by a 
cutoff of 0.60 nm (ContP-P). Standard deviations were reported in parenthesis.  
 Length Rg Rg,BB Rg,MI Rg,MII CCS SA COMP-P HBP-P HB ContP-P 
[hIns2]6+ 
75 1.30(0.01) 1.25(0.01) 1.01(0.01) 0.99(0.01) 12.8(0.2) 69.24(1.76) 1.66(0.02) 14.8(1.9) 90.7(5.0) 492.9(50.5) 
35 1.31(0.01) 1.26(0.01) 1.02(0.01) 1.01(0.01) 12.9(0.2) 69.53(1.28) 1.64(0.02) 13.7(2.1) 91.5(5.9) 529.2(55.0) 
35 1.27(0.01) 1.23(0.01) 1.02(0.01) 0.98(0.01) 12.6(0.1) 68.01(1.16) 1.55(0.02) 13.4(1.8) 90.3(5.0) 587.5(44.7) 
[hIns2]Gro6+,a 25 1.20(0.01) 1.16(0.01) 0.97(0.01) 1.01(0.01) 11.7(0.3) 64.54(1.91) 1.35(0.03) 17.3(3.1) 89.3(5.8) 604.9(75.2) 
hIns2,watb 0.1 1.37(0.01) 1.32(0.01) 1.03(0.01) 1.03(0.01) 16.9(0.1) 76.84(1.95) 1.82(0.03) 5.2(1.4) 64.2(4.1) 510.1(10.1) 
a Structural properties of hIns2 obtained from gas-phase MD simulations using GROMOS force field. 
b Structural properties of hIns2 obtained from MD simulations in water.  
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Table A6: CCS values (in nm2) for various hIns2 structures and snapshots taken from 
the 0.075 ms long MD simulations in the gas phase. 
 
 CCS 
X-raya 16.6 
Rep_waterb 16.9 
Expc 12.9 
0 µs 13.4 
0.9 µs 12.7 
5.7 µs 12.6 
8.1 µs 12.7 
27.6 µs 12.6 
31.2 µs 12.4 
36.3 µs 12.6 
42.6 µs 13.0 
54.9 µs 12.9 
75.0 µs 12.8 
a The hIns2 X-ray structure at 1.0 Å (PDB ID: 1MSO[321]).  
b The representative structure from our MD simulation in solvent. 
c The experimental CCS value from ref. [299].  
 
Table A7: The number of all the possible protonation states for various charge states 
(q=1+ to q=15+) of hIns2 calculated by using the equation in ref. [300] are reported. 
 
q Number of protonation states 
15+ 4,060 
14+ 22,950 
13+ 132,084 
12+ 578,595 
11+ 2,018,376 
10+ 5,838,174 
9+ 14,298,020 
8+ 30,040,989 
7+ 54,626,100 
6+ 86,493,008 
5+ 119,759,832 
4+ 145,422,675 
3+ 155,117,520 
2+ 145,422,675 
1+ 119,759,850 
 
Table A8: GB corrected force field energy differences (ΔEcorr) of the pairs of 
conformers whose DFT energy difference (ΔEDFT) is within 10 kJ/mol. 
Index ΔEcorr (kJ/mol) 
1 -124.9 
2 -48.4 
3 -78.5 
4 -3.9 
5 -79.0 
6 -115.4 
7 -21.6 
8 -44.9 
9 -123.9 
10 -79.0 
11 -26.4 
12 -110.2 
13 -38.1 
14 -235.3 
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Table A9: Average structural properties of MD simulations in the gas phase of hIns2 
at the main charge state with the most probable protonation states. From left to right: 
radius of gyration (Rg in nm); radius of gyration of backbone atoms (Rg,BB in nm); 
radius of gyration of monomer I (Rg,MI in nm); radius of gyration of monomer II 
(Rg,MII in nm); collision cross section (CCS in nm2); total surface area (SA in nm2); 
center-of-mass distance between monomers (COMP-P in nm); number of hydrogen 
bonds in protein-protein interface (HBP-P); number of hydrogen bonds in complex 
(HB); number of hydrogen bonds in complex (HB); number of contact pairs between 
the carbon atoms of the monomers defined by a cutoff of 0.60 nm (ContP-P). Standard 
deviations are reported in parenthesis. 
 Rg Rg,BB Rg,MI Rg,MII CCS SA COMP-P HBP-P HB ContP-P 
Prot 1 1.30(0.01) 1.25(0.01) 1.01(0.01) 0.99(0.01) 12.8(0.2) 69.24(1.76) 1.66(0.02) 14.8(1.9) 90.7(5.0) 492.9(50.5) 
Prot 2 1.33(0.01) 1.29(0.01) 1.05(0.01) 1.01(0.01) 13.3(0.2) 70.25(1.37) 1.73(0.02) 12.5(1.6) 91.9(4.6) 535.0(34.6) 
Prot 3 1.29(0.01) 1.25(0.01) 1.00(0.01) 1.02(0.01) 13.0(0.1) 70.23(1.13) 1.61(0.03) 14.6(1.8) 91.8(4.4) 561.1(22.7) 
Prot 4 1.25(0.01) 1.20(0.01) 1.05(0.01) 1.00(0.01) 12.6(0.2) 68.22(1.68) 1.34(0.03) 13.1(1.9) 96.0(5.2) 587.4(40.3) 
Prot 5 1.25(0.01) 1.20(0.01) 1.02(0.01) 1.00(0.01) 12.7(0.1) 67.41(1.33) 1.42(0.01) 16.2(1.7) 85.6(4.0) 661.9(25.3) 
hIns2,wata 1.37(0.01) 1.32(0.01) 1.03(0.01) 1.03(0.01) 16.9(0.1) 76.84 (1.95) 1.82(0.03) 5.21(1.4) 64.2(4.1) 510.1(10.1) 
a Structural properties of hIns2 obtained from MD simulation in water. 
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